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1 Introduction 
The concept of the metabolic syndrome (MetSyn) - also known as insulin resistance 
syndrome (IRS) [BALKAU and CHARLES, 1999], syndrome X [REAVEN, 1988] and 
cardiometabolic syndrome [SOOKOIAN and PIROLA, 2007] - is defined as a cluster of 
metabolic abnormalities in an individual. Which metabolic abnormalities and which 
corresponding threshold levels are to consider is still in a debate; however, in general 
major scientific associations agree on the essential components of the syndrome 
including obesity, glucose/insulin disturbance, dyslipidemia and hypertension. 
The MetSyn is predictive of an increased risk of cardiovascular disease (CVD) and of 
type 2 diabetes mellitus (T2DM) [LORENZO et al., 2007], itself an important risk 
factor for CVD. Consequently, the increasing prevalence is an important public health 
issue; at least for those scientists who believe in the existence of a MetSyn. For others, 
the MetSyn is not more than the sum of its components; therefore, they question the 
usefulness to diagnose somebody with the MetSyn at all.  
However, the MetSyn is not a new condition. Its history goes back to 1923 when Kylin 
described it first as an association of hypertension, hyperglycaemia, and gout [KYLIN, 
1923]. In 1988, Reaven termed the condition in his Banting Lecture “syndrome X”. He 
described it as a syndrome comprising a dysregulated glucose and insulin homeostasis, 
hypertension, and dyslipidemia [REAVEN, 1988]. In the course of time scientific 
associations have proposed several MetSyn definitions and obesity was added as an 
essential component. As aforementioned, all agree on the essential components, but the 
definitions either require obesity or insulin resistance (IR) or no special criteria for the 
diagnosis of the MetSyn. Furthermore, they distinguish themselves by the different 
proposed threshold values. 
If one assumes, that there really is a MetSyn and it is necessary to fight against the 
increasing prevalence, two targets are indicated, along to the treatment of the disease: 
environmental factors and genetic factors. The interplay of those two factors seems to 
be causative for the MetSyn. The question arising is where to start? Should we try to 
change the environmental factors in general and so prevent other diseases too? Sadly, 
this is not so easy, if so, we would not have the epidemic obesity. Other ways have to be 
found to prevent the MetSyn. Hence, one has to look at the second target, the genetic 
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factors. It is assumed that when someone is discovered by genetic screening to be a 
person at risk for the development of the MetSyn, he or she is more willing to change or 
to improve environmental factors such as dietary fat intake. In this respect, the genetic 
assessment followed by individualised healthy lifestyle recommendations for at-risk 
persons is a useful way to prevent the MetSyn.  
Preventing a common disease than just treating a common disease is most important. In 
addition to the public health perspective, that it is more cost effective to prevent than to 
treat a common disease, one has to notice the individual perspective too. CVD and 
T2DM influence the quality of life of affected individuals and their families. A healthy 
person is (mostly) a happier and more satisfied person and that - in turn to the public 
health perspective improves - among other things - manpower productivity.  
 
For that reasons this thesis is to investigate the genetically susceptibility for the MetSyn 
along with other questions such as whether the diagnosis of the MetSyn is more 
predictive than the diagnosis of its single components or whether there is a MetSyn 
definition that is better than the others; but principally it is investigated which genes or 
gene variants are associated with the MetSyn or its components by reviewing gene-wide 
association studies (GWASs). 
 
Who’s at risk? 
 
 
 
 
 
 
 
 
Source: http://www.nature.com/nrg/journal/v8/n12/images/nrg2280-i1.jpg 
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2 Literature survey 
2.1  Definitions of the MetSyn 
Many definitions of the MetSyn have been proposed by scientific associations in the last 
years. They all agree on the essential components of the syndrome including obesity, 
glucose/insulin disturbance, dyslipidemia, and hypertension, but they also have distinct 
differences (Table 1). In the following part, the most important definitions are reviewed.  
 
2.1.1 WHO 
In 1999, the World Health Organization (WHO) published a definition of the MetSyn 
with focus on IR. The definition was suggested to be a working definition that has to be 
improved in due course. Glucose intolerance, impaired glucose tolerance (IGT) or 
diabetes mellitus and/or IR together with at least two of the following criteria are 
required for a positive diagnosis: IGT or diabetes, IR, impaired fasting glucose, central 
obesity (assessed by waist to hip ratio or by Body Mass Index), dyslipidemia, raised 
arterial pressure, and microalbuminuria (Table 1). They had noticed that several other 
components of the MetSyn have been described (e.g. coagulation disorders, 
hyperuricaemia); still, they believed that these components are not necessary for the 
recognition of the condition [WHO CONSULATION, 1999]. 
 
2.1.2 EGIR 
Few months after the WHO definition was published, the European Group for the Study 
of Insulin Resistance (EGIR) modified the definition and suggested that insulin 
resistance syndrome (IRS) would be a more appropriate name for the syndrome. They 
had focused in their definition on IR (IR as defined as “the 25% of the non-diabetic-
population with the highest insulin resistance or the highest fasting insulin 
concentration”) as well, but they dropped the criterion for microalbuminuria and 
included treatments for hypertension and dyslipidemia as criteria (Table 1). IR and two 
other criteria are required for the MetSyn diagnosis. Interestingly, EGIR excluded 
patients with T2DM from their MetSyn definition because they believed that there is no 
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simple way to measure IR in individuals with diabetes [BALKAU and CHARLES, 
1999]. 
 
2.1.3 NCEP-ATP III 
The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III-ATP III) of the National Cholesterol Education 
Program (NCEP) published their definition in 2001 and revised it in 2004. At least three 
of the following five criteria are required to be present: abdominal obesity, 
hypertriglyceridemia, reduced HDL-C levels, hypertension, and impaired fasting 
glucose (Table 1). In contrast to the former definitions, this definition neither requires 
the presence of IR nor obesity [GRUNDY et al., 2004]. 
 
2.1.4 AACE/ACE 
In 2003, the American College of Endocrinology Task Force published a MetSyn 
definition, or as they prefer to say an IRS definition, in a position statement. This 
position statement reflected a commitment of the American Association of Clinical 
Endocrinologists (AACE) and the American College of Endocrinology (ACE). 
AACE/ACE adopted the blood pressure and lipid criteria from the NCEP-ATP III 
definition, but suggested modifications on other parts of the definition. Interestingly, 
they did not include any criteria for obesity in their definition (Table 1). They also did 
not indicate a number of risk factors that have to be found in a person for the diagnosis 
of the MetSyn. AACE-ACE stated that “the diagnosis of the MetSyn should be 
considered in any individual with risk factors and abnormalities” (plasma glucose 
disturbances, raised triglycerides, lowered HDL cholesterol and hypertension). For 
epidemiological purposes, however, they concluded that the MetSyn affects an 
individual when two or more abnormalities are present at the same time. Additionally, 
AACE/ACE encouraged the use of an elevated 2-hour post-challenge glucose test when 
individuals at risk (list below) do not sufficiently meet other criteria for MetSyn and a 
more sensitive test may be needed [EINHORN, 2003]. 
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Risk factors that increase the likelihood of having the MetSyn: 
• Overweight: 
o BMI: >25 kg/m2 or  
o Waist circumference: >102 cm (men), >88 cm (women) 
In each case 10-15% lower for non-Caucasians 
• Sedentary lifestyle 
• Age: >40 years 
• Non-Caucasian ethnicity: e.g. Latino/Hispanic American, African American  
• Family history of T2DM, hypertension or CVD 
• Family history of glucose intolerance or gestational diabetes 
• Acanthosis nigricans 
• Polycystic ovary syndrome 
• Nonalcoholic fatty liver disease 
[EINHORN, 2003] 
 
2.1.5 IDF 
The International Diabetes Federation 2005 had focused in their definition of the 
MetSyn on central obesity. This criterion and at least two others are required for the 
diagnosis of the MetSyn (Table 1). IR has not to be present. Interestingly, they 
established several ethnicity specific cut-off points for high waist circumference. For 
example, in Europids a waist circumference ≥ 94 cm (male) is seen as high, whereas ≥ 
90 cm (male) is the risk threshold for South Asians [IDF, 2006]. 
 
2.1.6 AHA/NHLBI 
In “Diagnosis and Management of the Metabolic Syndrome: An American Heart 
Association/National Heart Lung, and Blood Institute Scientific Statement” a further 
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definition was published in 2005. For the diagnosis of the MetSyn, at least three criteria 
are required (Table 1). Like the NCEP-ATPIII definition, this definition does not 
require the presence of one special criterion. Ethnic cut-off points for waist 
circumference are not defined, but they recommend lower cut-off-points for Asian 
Americans (80 cm in women, 90 cm in men) [GRUNDY et. al, 2005].  
 
Table 1. Diagnostic criteria for the MetSyn  
Criteria WHO 
(1999) 
EGIR 
(1999) 
NCEP-
ATPIII 
(2001/04) 
AACE/ 
ACE 
(2003) 
IDF 
(2005) 
AHA/ 
NHLBI 
(2005) 
IR Presence Presence     
IFG (FPG) 
or IGT (2h 
PG) mmol/L 
≥ 6.1 
≥ 7.8 
or DM 
≥ 6.1, but 
nondiabetic 
 
≥ 5.6 61-6.9 
7.7-11.0 
 
≥ 5.6 
or T2DM 
≥ 5.6 
or RX 
Waist (cm) 
or WHR 
> 0.9 
(> 0.85) 
≥ 94 
(≥ 80) 
> 102  
(>88) 
 ≥ 94 
(≥80)* 
≥ 102 
(≥88)* 
BMI 
(kg/m2) 
> 30      
BP  
(mmHG) 
≥ 140/90 ≥ 140/90 
or RX 
≥ 130/85 > 130/85 ≥ 130/85 
or RX 
≥ 130/85 
or RX 
TG 
(mmol/L) 
≥ 1.7 ≥ 2.0 
 or RX 
≥ 1.7 > 1.7 ≥ 1.7  
or RX 
≥ 1.7  
or RX 
HDL-C 
(mmol/L) 
< 0.9 
(<1.0) 
<1.0  
or RX 
<1.03 
(<1.29) 
<1.03 
(<1.29) 
≤1.03 
(≤1.29) 
or RX 
≤1.03 
 (≤1.3) 
or RX 
UAER 
(µg/min) 
 or A/C 
(mg/g) 
≥ 20 
 
≥ 30 
     
WHO World Health Organization; EGIR European Group for the Study of Insulin Resistance; 
NCEP-ATPIII National Cholesterol Education Program-Adult Treatment Panel III; 
AACE/ACE American Association of Clinical Endocrinologists/American College of 
Endocrinology; IDF International Diabetes Federation; AHA/NHLBI American Heart 
Association/National Heart Lung, and Blood Institute 
A/C albumin/creatinine ratio; BMI body mass index; BP blood pressure; DM diabetes 
mellitus; FPG fasting plasma glucose; HDL high-density lipoprotein cholesterol; IFG 
impaired fasting glucose; IGT impaired glucose tolerance; IR insulin resistance; PG plasma 
glucose; RX receiving treatment; TG triglycerides; UAER urinary albumin excretion rate; 
WHR waist:hip ratio 
* in Europids; values in brackets for females 
[DAY, 2007] modified 
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2.2 Prevalence of the MetSyn  
At the first glance the MetSyn-definitions do not seem to be extremely different, 
nevertheless, on closer examination distinct differences appear [DAY, 2007]. Only 
33.9% of a population, which individuals were diagnosed with the MetSyn at least by 
one definition, fulfilled all three investigated definitions (EGIR, WHO, NCEP) (Figure 1). 
Furthermore to the rather small overlapping of the diagnosed individuals, it is to notice 
that the assessed prevalence rates differ considerably. The DECODE Study Group 
compared different definitions of the MetSyn in relation to cardiovascular mortality in 
European men (n = 4,715) and women (n = 5,554). They showed that the prevalence of 
the MetSyn according to definitions of WHO, NCEP-ATPIII, NCEP-ATPIII revised 
(FPG cut-off value was lowered from 6.1mmol/l to 5.6 mmol/l) and IDF was 27.0%, 
25.9%, 32,2% and 35.9% respectively in men and 19.7%, 23.4%, 28,5% and 34.1% 
respectively in women [THE DECODE STUDY GROUP, 2006]. Other studies also 
showed that the IDF definition tends to higher prevalence rates in Europeans compared 
to previously established definitions [ATHYROS et al. 2005; LAWLOR et al., 2006]. 
The lower threshold for high blood pressure and obesity could explain this effect 
[LAWLOR et al., 2006]. In contrast, the comparison of the IDF definition with the 
AHA/NHLBI definition showed that the IDF definition tends to smaller prevalence 
rates as it was shown in a study conducted in Singapore (n = 4,723). The prevalence of 
the MetSyn by the IDF definition was 20,2 % and 26,9% by the AHA/NHLBI definition 
[KHOO et al., 2007]. 
 
Figure 1. Agreement and 
disparity in the diagnosis 
of the MetSyn 
using the modified WHO 
definition, the EGIR 
definition, and the NCEP 
definition among 1,503 
women who qualified for the 
diagnosis of the MetSyn by 
at least one of these 
definitions.[THE DECODE 
STUDY GROUP, 2005] 
modified 
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As pointed out above, the assessed prevalence rates vary substantially by using different 
definitions in addition to the variation caused by different study populations and 
different study design. As a result, the comparison of studies is more complicated than 
usual. 
 
Independently from the definitions, it has been shown that the worldwide prevalence of 
the MetSyn is increasing [LEVESQUE and LAMARCHE, 2008], largely because of the 
rise in obesity rates, and that the MetSyn is age-dependent [FORD et al., 2002; THE 
DECODE STUDY GROUP, 2005]. That means: the older the individuals, the higher 
the MetSyn prevalence (Figure 2).  
 
Figure 2. Age-specific prevalence of the MetSyn among 8,814 US adults  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[FORD et al., 2002] reproduced 
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2.3 Clinical relevance of the MetSyn  
The MetSyn is predictive of an increased risk of CVD and T2DM [LORENZO et al., 
2007], itself an important risk factor for CVD; still, it is not yet clear which MetSyn-
definition predicts best. It is even not clear whether there is a need to predict the risk by 
diagnosing the MetSyn, because there are already established risk predicting models for 
CVD (Framingham Risk Score) and T2DM (Diabetes Risk Score). Finally, the 
existence of a MetSyn is in question, because some think that it is not more than the 
sum of its components. In the next part, this will be discussed in more detail. 
 
2.3.1 Prediction of CVD and T2DM 
In the beginning, it seems that the definitions do not have comparable power to predict 
CVD or T2DM.  
The IDF definition appears to be a less powerful CVD predictor [LEVESQUE and 
LAMARCHE, 2008; KHOO et al., 2007], but a good predictor of increased T2DM risk 
[KHOO et al., 2007].  
The WHO definition has been shown to predict T2DM better than the NCEP-ATPIII 
definition [STERN et. al, 2004]. In addition, it was shown by two meta-analyses that the 
WHO definition tends to stronger associations between the MetSyn and CVD than the 
NCEP-ATPIII definition [GAMI et al., 2007; GALASSI et al., 2006]. The more recent 
and larger meta-analysis showed that the RR of incident cardiovascular events and death 
was 2.06, 1.67, and 1.35 for the WHO definition, the NCEP-ATPIII definition and for 
other definitions respectively. Noteworthy, the association was stronger in women and 
in studies including lower risk (<10%) individuals. However, significant heterogeneity 
between the pooled studies existed and, therefore, the results are to question [GAMI et 
al., 2007]. The second meta-analysis reported 1.54 (95% CI 1.30-1.81; P < 0.001) as 
overall RR of CVD associated with the MetSyn (WHO and NCEP-ATPIII definition) 
when analysing the 14 studies that controlled for important confounders (age, sex, race, 
cigarette smoking). The unadjusted CVD RR was 1.61 (95 % CI 1.42-1.83) and 1.82 
(1.27-2.61) for the ATPIII definition and the WHO definition respectively [GALASSI 
et al., 2006].  
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The opposite was shown by the San Antonio Heart Study (SAHS, n = 2,559), because 
here the NECP-ATPIII definition showed the strongest association for incident CVD 
risk followed by the WHO and the IDF definition, particularly in men aged ≥ 45 years 
and women aged ≥55 years. The power of the MetSyn to predict diabetes was larger 
than the power to predict CVD (Figure 3) and was again strongest for the NCEP-ATPIII 
definition, followed by the WHO and the IDF definition [LORENZO et al., 2007].  
 
Figure 3. MetSyn predicts incident diabetes and incident CVD 
Data from Lorenzo et al.  
Diabetes: NCEP-ATPIII (OR 6.90; 95% CI 4.97–9.58), IDF (OR 5.76; 95% CI 4.11–
9.07), WHO (OR 6.67; 95% CI 4.75–9.35), adjusted for age, sex, ethnic origin, history 
of CVD and T2DM, non-HDL cholesterol, smoking status, and family history of heart 
attack;  
CVD: NCEP-ATPIII (OR 2.00; 95% CI 1.33–3.01), IDF (OR 1.69; 95% CI 1.13–2.54), 
WHO (OR 1.73; 95% CI 1.12–2.67) adjusted for age, sex, ethnic origin, and family 
history of diabetes. 
0,0
0,5
1,0
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Moreover, Lorenzo et al. indicated the importance to assess sensitivities and false 
positive rates, when comparing the different definitions. They found that the three 
definitions (WHO, IDF, NCEP-ATPIII) predict T2DM and CVD rather similarly; 
however, they predict the diseases with different sensitivities and FPRs (Figure 4) 
[LORENZO et al., 2007]. Sensitivities, false-positive rates, and aROCs (area under the 
received operating characteristic curve) are seen as better methods, than ORs (RRs or 
HRs), to assess the significance of a potential new risk factor [STERN et al., 2004]. 
 
Figure 4. ROC for predicting diabetes for the 2-h glucose value and sensitivity and 
FPR of IGT, IFG, and MetSyn 
The ATPIII definition was less sensitive (P < 0.001) and more specific (P < 0.001) 
compared to the IDF definition. The difference in sensitivity between ATPIII and WHO 
definitions was close to significant (P = 0.058), but the WHO definition was more 
specific (P = 0.014). 
 
 
[LORENZO et al., 2007], reproduced  
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2.3.2 Diabetes Predicting Model and Framingham Risk Score 
Years before Lorenzo et al. encouraged the use of sensitivities, false-positive rates and 
aROCs, Stern et al. called for the same in a publication that shaded a rather negative 
light on the benefit of the MetSyn. They compared the MetSyn, defined by the NCEP-
ATP III, to the Diabetes Predicting Model and the Framingham Risk Score as predictors 
of T2DM and CVD respectively, and found that even though the MetSyn can predict 
T2DM and CVD, it predicts less effectively (lower sensitivity and higher false-positive 
rate) than the Diabetes Risk Score and the Framingham Risk Score. Moreover, the 
combination of these predicting models with the MetSyn does not significantly improve 
the prediction value of the risk scores [STERN et. al 2004].  
The opposite was shown by the DECODE Study Group; they justified in men the use of 
the MetSyn in clinical practice. The study purpose was to investigate if the MetSyn 
detect further men at risk of cardiovascular death beyond those identified by a risk score 
and the MetSyn did. Men with a low cardiovascular risk score and the MetSyn had a 
significantly higher risk of fatal CVD than those without the syndrome. Anyhow, the 
diagnostic tool waist circumference is easier to assess and showed a similar fatal CVD 
risk. A waist circumference larger than 102 cm was related to an OR of 2.24 (1.05-4.76) 
whereas the significant HR for fatal CVD, after adjusting for age and study centre was 
2.71 (1.33-5.51) for men affected by the MetSyn [THE DECODE STUDY GROUP, 
2007].  
Positive aspects regarding the MetSyn were also shown by Lorenzo et al. Their study 
results lead to the assumption that the MetSyn may complement Framingham scoring 
for men aged ≥ 45 years and women aged ≥ 55 years. Furthermore, they suggested that 
the MetSyn is particularly useful for predicting diabetes. This was due to the reason that 
the MetSyn added to a predicting model including 2h- and fasting glucose levels. It 
follows that the T2DM prediction is not only by glucose intolerance [LORENZO et al., 
2007]. 
In the joint AHA-NHLBI statement, it was already previously (in 2005) noticed that the 
MetSyn per se is not a sufficient tool to estimate the risk for CVD, but the diagnosis of 
the syndrome is seen as one part of the overall risk assessment. In MetSyn patients 
without atherosclerotic cardiovascular disease or diabetes, the Framingham Risk Score 
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should be applied to estimate 10-year risk for CVD. The diagnosis of the MetSyn 
should, in contrast, predict a long-term risk for CVD [GRUNDY et al., 2005]. For 
individuals with long-term or higher lifetime risk lifestyle modifications (weight loss, 
increased physical activity, healthy diet) should be emphasized, because those 
individuals could particularly benefit from early prevention. If the short-term risk of 
CVD or diabetes is high, as assessed with the Framingham Risk Score or the Diabetes 
Risk Score, the altering of specific risk factors due medication should be considered 
[LEVESQUE and LAMARCHE 2008], but lifestyle modifications should also be 
emphasized for those individuals. 
 
Regarding to the overall risk assessment of cardiovascular risk researchers defined the 
summation of risks conferred by the MetSyn and traditional risk factors as global 
cardiometabolic risk; however, they also pointed out that the additive value of the 
MetSyn to such a global cardiometabolic risk is unclear [DESPRÉS and LEMIEUX, 
2006]. 
 
Figure 5. The global cardiometabolic risk and its contributing factors 
 
 [DESPRES and LEMIEUX, 2006] reproduced 
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2.3.3 Is the MetSyn more than the sum of its components? 
The inferiority to the Framingham risk score to predict short time risk is not the only 
criticism passed on the MetSyn. Studies found that the HRs (CVD) for the individual 
components of the syndrome were similar or lager than the HRs for the whole syndrome 
[THE DECODE STUDY GROUP, 2006; LAWLOR et al., 2006].  
Opposite to this findings the authors of a recent meta-analysis of 37 longitudinal studies 
(n = 172,573), which assessed the association between the MetSyn and cardiovascular 
events and mortality, reported that the cardiovascular risk, which is related to the 
MetSyn as a whole syndrome is beyond that, which is associated with the risks 
conferred by the single components. The pooled results of three studies that 
simultaneously adjusted for MetSyn and some of its components showed an increased 
risk of CVD or death in patients with MetSyn (RR 1.54, 95% CI 1.32-1.79) [GAMI et 
al., 2007].  
 
2.3.4 MetSyn as a reminder 
Last but not least, the term MetSyn serves in a very practical way. It reminds physicians 
to investigate whether there are additional risk factors due to the presence of one risk 
factor. That the further investigation is important was, for instance, shown by a small 
study conducted in Scotland (n = 356). The researchers investigated whether 
undiagnosed IGT/IFG and T2DM is common amongst patients with ischaemic heart 
disease and patients with hypertension. They found that in primary care patients 
(diagnosed with hypertension) 2% have undiagnosed T2DM and 18.5% have IFG 
and/or IGT. In other words, testing 50 patients identifies one new case of T2DM and 
testing six patients identifies one new case of IFG or IGT. The results were very similar 
in patients diagnosed with ischaemic heart disease [SAVAGE et al., 2003]. 
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2.4 Driving and underlying factors of the MetSyn  
It is currently unknown which components of MetSyn are primary and which are 
secondary, but visceral obesity is believed to be a driving factor for the syndrome 
(Table 2). In consequence of visceral obesity, one can develop IR and T2DM [GURI et 
al., 2008; SONG et al., 2006]. The term IR refers to a state of insulin action 
dysfunction. This state is followed by hyperinsulinaemia (increased insulin secretion by 
pancreatic beta cells) to uphold normal glucose tolerance. If the elevated rate of insulin 
secretion cannot be held, a decrease of the fasting insulin concentration occurs. This 
subsequently results in impaired glucose tolerance and finally in T2DM [KASHYAP 
and DEFRONZO, 2007].  
Obesity also contributes to other risk factors clustered in the MetSyn (hypertension, 
increased TG level, decreased HDL-C level). Moreover, adipose tissue is an endocrine 
organ. It secretes adipocytokines into the circulation and it influences inflammatory 
markers, such as C-reactive protein, leading to a proinflammatory state. 
 
Table 2. The overflow hypothesis  
The capacity of adipocytes to store fat is limited; therefore, an overflow of fat (free fatty 
acids) occurs when excess fat is in the metabolism.  
overflow to  consequence: 
Muscle  insulin resistance 
Liver  increased hepatic glucose production 
Pancreas  decreased insulin secretion 
Arteries  arteriosclerosis 
[KASHYAP and DEFRONZO, 2007] modified 
 
On the other hand, IR is discussed as a driving factor. This is underpinned by the 
proposed synonym of the MetSyn: insulin resistance syndrome. In an insulin-resistant 
state, an impairment of insulin to inhibit lipolysis occurs, this results in constantly 
elevated plasma free fatty acids (FFAs). As shown above FFAs have a central role in 
the syndrome. It was even shown that IR causes T2DM. This happens through 
metabolic and cardiovascular changes, which can also lead to obesity, dyslipidemia, 
CAD, and hypertension [KASHYAP and DEFRONZO, 2007]. 
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MetSyn 
obesity hyptertension disturbed glu/ins dyslipidemia 
Genetic 
variations 
Environmental 
factors 
Even it is not clear whether visceral obesity or IR is primary, it is believed that the 
interplay of environmental factors and genetic variations is causative for the MetSyn 
(Figure 6) [SONG et al., 2006].  
That environmental factors are at play is easy to understand, since the human genome 
has not changed markedly in the last decades, but the prevalence of the MetSyn has 
drastically increased. Furthermore, it is seen that changing to healthy eating habits 
improves the most metabolic abnormalities of the MetSyn [PHILLIPS et al., 2008]. 
That genes play an important role in the development of the MetSyn is pointed out by a 
simple consideration. There are individuals with the same healthy or unhealthy life 
circumstances and possibly the same BMI and/or fatmass and/or fat distribution, but not 
everybody from the “unhealthy” group comes down with the MetSyn and not 
everybody from the “healthy” group is protected. Those two groups might have a 
different genetic background, different genetic variations that lead for example to 
protection through improved insulin sensitivity. Furthermore, heritability estimates for 
the MetSyn and its components indicate a genetic contribution. This is shown in the 
next part. 
 
 
Figure 6. Factors influencing the MetSyn 
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2.5 Heritability of the MetSyn 
That the MetSyn has to have a component of heritability was shown in a number of 
investigations and is emphasized by the familial nature and the obvious differences in 
the prevalence of the MetSyn among various populations. Mexican Americans, for 
example, are particularly at risk to develop the MetSyn [STERN et al., 2004; FORD et 
al., 2002]. Heritability is defined as “the proportion of phenotypic variation of a trait 
that can be attributed to genetic variation” [SOUREN et al., 2007].  
 
Several studies have provided estimates for the degree to which the metabolic 
abnormalities of the MetSyn can be explained by heritability. Freeman et al. conduced a 
study in 537 adults from 89 families in the UK (white North European population). The 
population was healthy (defined by absence of DM and overt vascular disease) and not 
characterized by a high degree of IR. Additionally to the investigation of genetic 
influences, they were particularly interested in environmental influences of the IRS. The 
highest significant heritability (adjusted for age, sex, BMI and smoking) was found for 
HDL-C (43%) and the lowest for systolic blood pressure (14 %) sharply followed by 
WHR (15%). In between (20-24%) were fasting glucose, insulin, estimated IR (fasting 
glucose x fasting insulin / 22.5), triglycerides, and LDL-C. Covariates explained 20-
25% of the variance of lipids and IR. Most remarkably, when the researchers accounted 
for the covariates, genetic and household effects, the remaining unexplained variance 
ranged from 32 % for HDL-C to 59 % for fasting glucose. That indicates that many 
uncovered factors e.g. additional environmental factors are at play and genes may not 
contribute that much to the MetSyn [FREEMAN et al., 2002]. Mills et al. reported 
heritabilities that were not significantly different from the heritabilities (adjusted for age 
and sex) reported by Freeman et al. except for the fasting glucose when investigating 
the same population. However, that time the sample had an increased susceptibility to 
T2DM (UK families: 811 non-diabetic relatives from 278 pedigrees) (Table 3) [MILLS 
et al. 2004]. 
That the HDL-C heritability is high was also shown in The Erasmus Rucphen Family 
study, which consists of 3,000 genealogically documented individuals from a Dutch 
genetic isolate. They found the highest heritability for HDL-C (42,9%, P < 0.0001) 
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followed by waist circumference (37.8%, P < 0.0001). Additionally, they investigated 
the heritability of the syndrome itself. They reported a significant heritability (10.6%) of 
the MetSyn according to IDF definition [HENNEMAN et al., 2008]. Previously an even 
higher significant heritability estimate (24%; adjusted for age and sex) for the MetSyn 
as defined by the NCEP-ATP III was reported in a study conducted in 803 subjects from 
89 Caribbean-Hispanic families, a high-risk population. This study also showed the 
highest heritability for HDL-C (60%) and the lowest heritability (16%) for systolic 
blood pressure after adjusting for age, sex, and medication [LIN et al. 2005].  
 
Table 3. Comparison of the heritability estimates for features of the IRS  
measured in the study of Mills et al. and Freeman et al. after adjustment for age and sex  
Features Mills et al. 
h
2
 
CoV 
%
# 
Freeman et al. 
h
2
 
CoV 
%
#
 
Difference 
h
2
 
BMI 0.52 0.48 0.37 7.00 0.15 
WHR 0.31 40.8 0.23 28.0 0.08 
Fasting glucose 0.77 14.6 0.21 14.0 0.56* 
Fasting insulin 0.30 1.30 0.29 1.00 0.01 
Triglycerides 0.40 7.40 0.19 11.0 0.21 
Log HDL 
cholesterol 
0.52 10.2 0.44 14.0 0.08 
Log LDL 
cholesterol 
0.57 19.9 0.33 20.0 0.24 
HOMA %S  0.29 1.50 0.31 3.00 -0.02 
Systolic BP 0.28 32.4 0.19 16.0 0.09 
CoV Covariates; h2 heritability estimate; HOMA %S homeostasis model assessment of 
insulin sensitivity = estimated IR 
#Percentage of variance explained by covariates; *P < 0.001 
[MILLS et al., 2004] modified 
 
Twin studies have considerable advantages compared to the aforementioned studies. 
They allow the splitting of variations into genetic, shared environmental and unique 
environmental components. Studies with MZ (monozygotic) twins offer the most valid 
estimations, because they share their common environment to the same degree and so a 
higher concordance rate in MZ twins than in DZ (dizygotic) twins reflects a genetic 
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contribution. Such twin studies came up with even higher heritability rates for metabolic 
abnormalities seen in the MetSyn than shown by the studies that used “only” relatives.  
 
The recently published “East Flanders Prospective Twin Survey” investigated 240 
healthy MZ- and 138 healthy DZ-twin pairs aged 18 to 34 years. The study aimed to 
determine the genetic contribution to T2DM. Therefore, they estimated the heritabilities 
of 18 anthropometric and metabolic characteristics related to this disease. They reported 
for obesity parameters (body mass, BMI, fat mass, sum of four skinfold thicknesses, 
WHR) adjusted heritabilities in the range of 70% to 85%. In that context, it is to notice 
that women had significantly lower heritabilities for body mass, BMI and fat mass. The 
adjusted heritability estimates for men and women were, furthermore, 67% for fasting 
glucose, 49% for fasting insulin, 48% for the homeostasis model assessment of insulin 
resistance, 62% for beta cell function, and finally 47% for the heritability of the insulin-
like growth factor binding protein-1 levels. The authors stated that this is the first twin 
study so far which reports a heritability of non-esterified fatty acid levels (37%). The 
estimated HDL-C was 76% and was thus between that of the heritabilities of total 
cholesterol, LDL-C, total cholesterol:HDL-C ratio and triglyceride and leptin levels, 
which ranged from 79 % to 53 % [SOUREN et al, 2007]. 
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2.6  Genome-wide association studies  
 
2.6.1 What are genome-wide association studies?  
That question was univocal answered by the National Institutes of Health. They defined 
the genome-wide association study (GWAS) as 
“any study of genetic variation across the entire human genome that is designed to 
identify genetic associations with observable traits (such as blood pressure or 
weight), or the presence or absence of a disease or condition. To meet the 
definition of a GWAS, the density of genetic markers and the extent of linkage 
disequilibrium should be sufficient to capture (by the r2 parameter) a large 
proportion of the common variation in the genome of the population under study, 
and the number of samples (in a case-control or trio design) should provide 
sufficient power to detect variants of modest effect” [NIH, 2007]. 
  
2.6.2 What are SNPs? 
Single nucleotide polymorphisms (SNPs) are the most common form of variation in the 
human genome. As many as 12 million have a reference SNP (rs) number in the 
National Centre for Biotechnology Information’s dbSNP database [NCBI, 2008a]. A 
SNP is the replacement of one nucleotide with another nucleotide. That changes the 
DNA sequence, for example from CTA to TTA (Figure 7).  
 
Figure 7. SNP   
DNA strand 1 differs from DNA strand 2 at a single 
base-pair location (a C/T polymorphism).  
 
 
Source: 
http://commons.wikimedia.org/wiki/Image:Dna-SNP.svg 
 
 
 
  
21 
The SNP is a non-synonymous one, when the changing of a single nucleotide leads to 
another amino acid and subsequently to another polypeptide sequence. If not so, the 
SNP is synonymous.  
In GWASs, hundreds of thousands of SNPs can be assayed by high-throughput 
genotyping technologies and then they are related to “observable traits or the presence 
or absence of a disease or condition” [NIH, 2007]. SNPs can increase or decrease the 
risk of disease; nevertheless, not all SNPs are functional. Functional SNPs, including 
missense coding SNPs and nonexonic regulatory SNPs, are assumed to contribute more 
likely to common diseases than non-functional SNPs [SONG et al., 2006]. 
 
The degree of linkage disequilibrium (LD) measures whether a SNP tends to be 
inherited together with another SNP more often than expected by chance. If LD is 
present, there is an association between alleles at different loci or in other words, there 
is a correlation between SNPs. A standard way to quantify the degree of that correlation 
is r2, showing the best correlation when r2 = 1 [FRAYLING, 2007b]. That correlation is 
important when one GWAS identifies SNP rsXX and another SNP rsXY to be 
associated with a disease. In that case, they can assume that they have found the same 
signal when rsXX and rsXY are in a perfect correlation (r2 =1). The HapMap (haplotype 
map of the human genome) catalogue provides a map of the correlation structure for 
common genetic variants, like SNPs. Moreover, their distribution among people within 
population and among populations in different parts of the world is described.  
Although LD helps to identify highly correlated SNPs in a chromosomal region, it is 
difficult to determine which SNP within the group is more likely to be the causative 
variant. It is also notable that the SNP with the best association within the group has not 
to be the causal variant. Another unknown (not genotyped) SNP in LD can be the 
causative one [FRAYLING, 2007b]. For that reason further gene investigations have to 
be carried out after an association via GWAS was found.  
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Figure 8. Pairwise LD diagram for the IDE-KIF11-HHEX  
The bar graph indicates the –log10 p values for association with T2DM for each SNP 
genotyped in the region; those reaching a prespecified value of P > 10-4 or greater are 
presumed to show association with disease. The region contains 1 “triangle” or “block” 
of LD. Pairwise LD estimates between SNPS are plotted for the region. The asterisks 
mark the SNPs chosen for confirmatory studies. 
 
 
 
 
[SLADEK et al. 2007] reproduced 
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2.6.3 Advantages of GWASs 
GWASs are a powerful method to identify totally novel susceptibility genes for 
common diseases – so non-Mendelian diseases -, because they permit a comprehensive 
scan of the genome without a hypothesis [PEARSON and MANOLIO, 2008]. There is 
no need for knowledge about gene function, pathophysiological pathways or molecular 
pathways of the investigated disease, but a need for a justified assumption that genes 
play a role in the development of the investigated disease. In addition to the 
identification of disease susceptibility genes in known gene regions, GWASs identify 
loci for common diseases and traits even in genomic regions containing no known genes 
[PEARSON and MANOLIO, 2008].  
As mentioned before GWASs identify genes that play a role in common diseases (or 
complex disorders). In common diseases not only one gene is responsible for the 
disease, several genes contribute to the disease development. Consequently, the 
responsible gene variants show, mostly, only modest increases in risk (moderate RR, 
OR or HR). GWASs are powerful enough to identify such modest increases [KEITH, 
2007].  
 
2.6.4 Candidate gene studies and linkage studies 
Candidate gene studies and linkage studies are two other well-known approaches to 
identify disease susceptibility genes. 
Candidate gene studies (CGSs) assay only a limited number of variants. Therefore, they 
need a hypotheses regarding genetic association with a disease. Related or unrelated 
individuals with and without disease are investigated. By contrast, linkage studies are 
always family-based, meaning family members with and without disease are 
investigated [PEARSON and MANOLIO, 2008]. This approach is valuable in finding 
genes for Mendelian conditions; however, it has only limited power to detect genes of 
modest or small effect underlying complex disorders. Thousands of sib-pairs would be 
required to identify such genes [HINNEY and HEBEBRAND, 2008]. To note is that in 
linkage studies logarithmic odds (LOD) are calculated. LOD is “a statistical estimate of 
whether 2 loci are likely to be located near each other on a chromosome; therefore, they 
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are likely to be inherited together. An LOD score of 3 means the odds are 1000 to 1 in 
support of genetic linkage” [SONG et al., 2006]. 
 
2.6.5 Carrying out GWASs 
To carry out a GWAS, researchers require DNA samples from thousands of participants 
(mostly case-control but also cohorts or family trios). Therefore, they take a blood 
sample or rub a cotton swab along the inside of the mouth to harvest cells. The DNA is 
then purified from the blood or cells and genotyped with microarrays, which can 
contain more than 500,000 SNPs. For that purpose, the DNA is placed on those 
microarrays and scanned on laboratory machines. Then the frequencies of each allele 
are compared among the study groups. If the allele frequencies differ statistically 
significant, a clue is given for the location of a disease-causing problem [NHGRI, 
2008b].  
The association of an allele with a disease can then be calculated with OR or RR, 
including different genetic models (dominant, recessive and additive). The most 
common genetic model seems to be the additive one. Here, each copy of the risk allele 
leads to a risk increase by the same amount. Last but not least the population 
attributable risk can be calculated, which can be seen as the “proportion of a disease or 
trait in the population that is due to a specific cause, such as a genetic variant“ 
[PEARSON and MANOLIO, 2008]. 
To ensure that the region of the human genome or the SNP identified in a GWAS is 
associated with the disease and reduce false positive rates, replication in independent, 
but very similar population, is necessary. Many studies are using for that reason 
multistage designs (Table 4) [PEARSON and MANOLIO, 2008].  
 
Table 4. Example of a hypothetical multistage design in GWAS: 3-stage study
 
Stage Case/Control SNPs Analysed 
1 400/400 500,000 
2 4,000/4,000 25,000 
3 20,000/20,000 25 
[PEARSON and MANOLIO, 2008] modified 
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2.6.6 Power to detect associations via GWAS 
Several factors influence the power to detect an association between a genetic variation 
and a disease: 
• Frequency of the risk allele or genotype 
The less frequent the allele, the more improbable it is to find an association. 
• RR or OR conferred by disease-associated allele or genotype 
The smaller the RR or OR, the more improbable it is to find an association. 
• Correlation between the genotyped marker and the risk allele 
The better the correlation, the more likely it is to find an association. 
• Disease prevalence 
The higher the prevalence, the more likely it is to find an association. 
• Genetic heterogeneity of the sample population  
The smaller the genetic heterogeneity, the more likely it is to find an association. 
It is clear that case and control populations should be as homogeneous as possible 
and that researcher must ensure that there is no misclassification. Cases have to be 
really affected by the disease and controls have to be truly disease free. This is 
particularly crucial for diseases that are difficult to diagnose reliably.  
• Sample size 
The bigger the sample size, the more likely it is to find an association. 
A sufficient sample size is – as power studies showed - at least 2,000 to 5,000 
samples for both cases and controls when using general populations. In less 
heterogeneous populations – like the Quebec Founder Population – only 1,000 to 
1,500 cases and controls are needed for a well-powered GWAS. The sample size 
challenges the recruitment of individuals with a similar phenotype and the matching 
of cases and controls with respect to genetic background. 
[KEITH, 2007]. 
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Additional key components to ensure a high study power are:  
• A large numbers of markers 
• Comprehensive maps, accurate high-throughput genotyping technologies 
• Sophisticated IT infrastructure (a GWAS produces terabytes of data), rapid 
algorithms for data analysis  
 [KEITH, 2007] 
 
Furthermore, it should be checked for genotyping errors: 
• The SNP call rate (the proportion of samples or SNPs for which a specific allele 
SNP can be reliably identified by a genotyping method) should be > 95%. 
• The minor allele frequency (= MAF, the frequency of the less common allele of 
a polymorphism) should be > 1% (in both cases and controls). 
• No severe violations of Hardy-Weinberg equilibrium should occur. 
• Mendelian inheritance errors in trio studies should be avoided. 
• The concordance rates in duplicate samples should be > 99.5%. 
 [PEARSON and MANOLIO, 2008] 
 
The numerousness of points stated above indicate that GWASs are prone to potential 
errors and therefore, one has to pay them attention. Otherwise, false-positive and false-
negative results occur. For instance, significant differences in population structure can 
lead to strong deviations from the null hypotheses (no SNP associated with the trait) and 
so to the misinterpretation that a SNP is highly associated with the trait [PEARSON and 
MANOLIO, 2008]. 
To avoid or better to reduce false-positive and false-negative results further, the 
replication of the findings is essential as well as the use of stringent levels of statistical 
significance. The importance of stringent levels is shown by a simple calculation. At the 
traditional P < 0.05 level of significance, an association study of 1 million SNPs will 
show 50,000 SNPs to be “associated” with disease just by chance. To reduce this high 
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false-positive rate, particularly when a multiple testing is performed, one can apply the 
Bonferroni correction, in which the traditional P < 0.05 value is divided by the number 
of tests performed. So for a GWAS testing 1,000,000 SNPs a P-value of < 5 x 10-8 
(0.05/1,000,000) would be suitable to confirm significant association [YANG et al., 
2005]. That would be certainly a very conservative correction, but that is not the only 
critic passed on the Bonferroni correction. It is further criticised because it relies on the 
assumption that every SNP association is independent although LD between individual 
SNPs exists [PEARSON and MANOLIO et al., 2008]. Another way to define a 
significance threshold was shown by Frayling. He stated in his review that a P-value of 
approximately < 5 x 10-7 should be the significance level for GWASs investigating 
T2DM. He based this threshold on the so far found genes, for which a replication was 
successful [FRAYLING et al., 2007a]. 
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2.7 Associated candidate genes  
In that chapter, an insight into the existing evidence linking gene variants, which protect 
or predispose individuals to the development of the MetSyn by reviewing GWASs is 
given. Unfortunately, no GWAS was published so far - to my knowledge - that 
investigated the association of gene variants with the MetSyn directly. Therefore, 
GWASs are reviewed that investigated gene associations with components of the 
MetSyn, C-reactive protein or with known outcomes, like T2DM, first. The most 
important associations are underpinned with results from candidate gene studies. 
Noteworthy is, that the focus is on studies conducted in Europeans or in populations of 
European ancestry. However, as the topic of this thesis is the MetSyn itself, direct gene 
associations were also investigated. That is the reason for the brief review of linkage 
studies at the end of this chapter that directly investigated the MetSyn. 
  
Table 5. Reviewed GWASs - Overview 
Study Disease/ 
Trait 
Initial 
Sample Size 
Replication 
Sample Size 
associated 
Gene – 
important 
examples 
P-value OR per copy or 
B-coefficient 
for HetZ and 
[95% CI] 
Bouatia-Naji 
et al., 2008  
FPG 654 
normoglycemic 
individuals 
9,353 
individuals 
G6PC2 4 x 10-23 0.06 [0.05-0.08] 
mmol/l decrease 
Chambers 
et al., 2008 
  
  
WC and 
related PT 
2,684 Asian 
Indian men 
11,955 
Asian Indian 
/ European 
individuals 
MC4R 2 x 10-9 0.88 [0.59-1.17] 
cm increase in 
WC 
Chen et al., 
2008  
FPG 5,088 
nondiabetic 
individuals 
18,436 
nondiabetic 
individuals 
G6PC2, 
ABCB11 
4 x 10-7 NR 
Fox et al. 
2007 
BMI 1,341 
individuals 
(Framingham) 
NR Intergenic  
 
Intergenic  
 
Intergenic 
1 x 10-7  
 
2 x 10-6  
 
8 x 10-6  
NR  
 
NR  
 
NR 
“ WC traits 1,341 
individuals 
(Framingham) 
NR GDAP1  
 
Intergenic 
2 x 10-7  
 
2 x 10-6  
NR  
 
NR 
Frayling et 
al., 2007  
BMI 10,657 adults 19,424 
adults, 
10,172 
children 
FTO 2 x 10-20 0.36 [NR] kg/m2 
per copy in 
adults  
Kathiresan 
et al. 2008 
HDL-C 2,758 
individuals 
18,544 
individuals 
GALNT2 2 x 10-13 0.07 [0.05-0.09] 
SD higher 
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Study Disease/ 
Trait 
Initial 
Sample Size 
Replication 
Sample Size 
associated 
Gene – 
important 
examples 
P-value OR per copy or 
B-coefficient 
for HetZ and 
[95% CI] 
Kathiresan 
et al. 2008 
LDL-C 2,758 
individuals 
18,544 
individuals 
CELSR2, 
PSRC1, 
SORT1 
 
CILP2, 
PBX4 
3 x 10-29  
 
 
 
3 x 10-8 
0.16 [0.14-0.18] 
SD lower  
 
 
0.10 [0.06-0.14] 
SD lower 
“ TG 2,758 
individuals 
18,544 
individuals 
BCL7B, 
TBL2, 
MLXIPL  
 
TRIB1  
 
 
GALNT2  
 
 
CILP2, 
PBX4  
 
ANGPTL3, 
DOCK7, 
ATG4C 
7 x 10-22  
 
 
 
4 x 10-17  
 
 
7 x 10-15  
 
 
4 x 10-9 
  
 
2 x 10-8 
0.14 [0.25-0.53] 
SD lower  
 
 
0.08 [0.06-0.10] 
SD lower  
 
0.08 [0.06-0.10] 
SD higher  
 
0.10 [0.06-0.14] 
SD lower  
 
0.11 [0.07-0.15] 
SD lower 
Kooner et al., 
2008 
TG 2,011 
individuals 
10,536 
individuals 
MLXIPL 1 x 10-10 10.50 [5.3-
17.7]% higher 
Levy et al., 
2007 
  
BP 644-1,327 
individuals, 
depending on 
measure 
(Framingham) 
NR Intergenic  
 
 
Intergenic  
 
 
Intergenic 
2 x 10-6 
(SBP)  
 
3 x 10-6 
(DBP)  
 
3 x 10-6 
(DBP) 
NR  
 
 
NR  
 
 
NR 
Liu et al., 
2008 
  
Obesity 1,000 
individuals 
896 obese 
individuals 
2,916 lean 
individuals  
NA NS NA 
Loos et al., 
2008 
 
BMI 16,876 
individuals 
60,352 
individuals 
MC4R 3 x 10-15 0.05 (0.04-0.06) 
unit increase in 
log (BMI) 
Ridker et al., 
2008 
 
 
 
 
 
 
 
 
 
 
 
CRP 6,345 women NR LEPR  
 
 
HNF1A  
 
 
GCKR  
 
 
 Unknown  
 
 
 
7 x 10-21  
 
 
7 x 10-17  
 
 
7 x 10-15  
 
 
1 x 10-10 
  
 
 
0.17 [NR] mg/dl 
decrease  
 
0.15 [NR] mg/dl 
decrease  
 
0.14 [NR] mg/dl 
increase  
 
0.12 [NR] mg/dl 
decrease  
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Study Disease/ 
Trait 
Initial 
Sample Size 
Replication 
Sample Size 
associated 
Gene – 
important 
examples 
P-value OR per copy or 
B-coefficient 
for HetZ and 
[95% CI] 
Ridker et al., 
2008 
  
IL6R 2 x 10-8 0.10 [NR] mg/dl 
decrease 
Sandhu et al. 
2008 
  
LDL-C 11,685 
individuals from 
5 GWAS 
5,036 
individuals 
CELSR2 1 x 10-33 0.15 [.13-.19] 
SD decrease in 
LDL 
Saxena et al., 
2007 
  
T2DM 1,464 cases, 
1,467 controls 
5,065 cases, 
5,785 
controls 
IGF2BP2  
 
CDKN2A, 
CDKN2B  
 
CDKAL1 
9 x 10-16  
 
8 x 10-15  
 
 
4 x 10-11 
1.14 [1.11-1.18]  
 
1.20 [1.14-1.25]  
 
 
1.12 [1.08-1.16] 
Scott et al., 
2007 
  
  
T2DM 1,161 cases, 
1,174 controls 
1,215 cases, 
1,258 
controls 
IGF2BP2  
 
CDKN2A, 
CDKN2B  
 
CDKAL1  
 
 
Intergenic 
9 x 10-16  
 
8 x 10-15  
 
 
4 x 10-11  
 
 
4 x 10-7 
1.14 [1.11-1.18]  
 
1.20 [1.14-1.25]  
 
 
1.12 [1.08-1.16]  
 
 
1.25 [1.15-1.37] 
Sladek et al., 
2007 
  
 
T2DM 1,380 cases, 
1,323 controls 
2,617 cases, 
2,894 
controls 
SLC30A8  
 
HHEX 
6 x 10-8  
 
3 x 10-6 
1.18 [0.69-1.67]  
 
1.19 [0.82-1.56] 
Steinthorsdott
ir et al., 2007 
  
T2DM 1,399 EA cases, 
5,275 EA 
controls 
2,437 EA 
cases, 7,287 
EA controls 
CDKAL1 8 x 10-9 1.20 [1.13-1.27] 
Willer et al., 
2008  
  
HDL-C 8,656 
individuals 
11,399 
individuals 
GALNT2  
 
 
MVK, 
MMAB 
3 x 10-14  
 
 
3 x 10-8 
1.11 [NR] mg/dl 
higher  
 
0.48 [NR] mg/dl 
higher 
“ 
  
LDL-C 8,589 
individuals 
7,440-
10,783 
individuals 
CELSR2, 
PSRC1, 
SORT1  
 
NCAN, 
CILP2  
 
B3GALT4 
6 x 10-33  
 
 
 
3 x 10-9 
  
 
5 x 10-8 
5.48 [NR] mg/dl 
higher  
 
 
3.32 [NR] mg/dl 
higher  
 
1.91 [NR] mg/dl 
higher 
“ 
 
 
 
 
 
 
 
 
 
TG 8,684 
individuals 
5,312-9,707 
individuals 
GCKR  
 
 
TRIB1  
 
 
MLXIPL  
 
 
 
6 x 10-32 
  
 
7 x 10-13  
 
 
2 x 10-12  
 
 
 
8.59 [NR] mg/dl 
higher  
 
6.42 [NR] mg/dl 
higher  
 
8.21 [NR] mg/dl 
higher  
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Study Disease/ 
Trait 
Initial 
Sample Size 
Replication 
Sample Size 
associated 
Gene – 
important 
examples 
P-value OR per copy or 
B-coefficient 
for HetZ and 
[95% CI] 
Willer et al., 
2008 
ANGPTL3  
 
 
NCAN, 
CILP2 
2 x 10-10  
 
 
3 x 10-9 
7.12 [NR] mg/dl 
higher  
 
6.10 [NR] mg/dl 
higher 
 WTCCC, 
2007  
  
HT 1,952 cases, 
2,938 controls 
NR RYR2, 
CHRM3, 
ZP4  
 
NR 
8 x 10-7 
  
 
 
6 x 10-6 
1.54 [1.03-2.31]  
 
 
 
1.03 [0.80-1.32] 
“ T2DM 1,924 cases, 
2,938 controls 
(see Zeggini 
2007) 
FTO  
 
CDKAL1  
 
NR  
 
NR  
 
NR 
2 x 10-7  
 
3 x 10-7  
 
3 x 10-6  
 
7 x 10-6  
 
7 x 10-6 
1.34 [1.17-1.52]  
 
1.18 [1.04-1.34]  
 
1.16 [1.03-1.33]  
 
2.50 [1.53-4.09]  
 
1.28 [1.11-1.49] 
Zeggini et al. 
2007  
  
T2DM 1,924 cases, 
2,938 controls 
3,757 cases, 
5,346 
controls 
IGFBP2  
 
CDKN2B  
 
FTO  
 
CDKAL1  
 
HHEX 
9 x 10-16  
 
8 x 10-15  
 
1 x 10-12  
 
4 x 10-11  
 
6 x 10-10 
1.14 [1.11-1.18]  
 
1.20 [1.14-1.25]  
 
1.17 [1.12-1.22]  
 
1.12 [1.08-1.16]  
 
1.13 [1.08-1.17] 
Zeggini et al., 
2008  
  
T2DM 4,549 cases, 
5,579 controls 
24,194 
cases, 
55,598 
controls 
JAZF1  
 
CDC123, 
CAMK1D  
 
TSPAN8, 
LGR5  
 
THADA  
 
ADAMTS9 
5 x 10-14  
 
1 x 10-10  
 
 
1 x 10-9  
 
 
1 x 10-9  
 
1 x 10-8 
1.10 [1.07-1.13]  
 
1.11 [1.07-1.14]  
 
 
1.09 [1.06-1.12]  
 
 
1.15 [1.10-1.20]  
 
1.09 [1.06-1.12] 
BMI body mass index; DBP diastolic blood pressure; DM incident diabetes mellitus; T2DM 
diabetes mellitus type 2; EA European-American; FI fasting insulin; HOMA-IR homeostasis 
model insulin resistance; HDL high density lipoprotein; HetZ heterozygous; HT hypertension; 
LDL low density lipoprotein; NA not applicable; NR none reported; NS not significant; OR 
odds ratio; PT phenotype; SBP systolic blood pressure; WC waist circumference 
 [NHGRI, 2008a] modified 
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2.7.1  T2DM, FPG, HOMA-IR% 
The interplay of environmental factors and genetic factors is thought to be responsible 
for the T2DM development. Genetic factors may predispose somebody, for example, to 
higher fasting plasma glucose (FPG) or reduced insulin secretion.  
Glucose and insulin metabolism regarding GWASs studied either genes that are 
associated with T2DM directly or associated with FPG. In addition, one GWAS, which 
was designed to investigate obesity related genes, showed an association with HOMA-
IR%. For that reasons this part is split up into genes associated with T2DM, genes 
associated with FPG, and genes associated with HOMA-IR%. 
 
Genes associated with type 2 diabetes mellitus 
In case of T2DM, GWASs recently lead to the identification of several novel gene 
associations. In 2007, five GWASs were published with convincing evidence for six 
new gene regions involved in T2DM [SLADEK et al, 2007; STEINTHORSDOTTIR et 
al., 2007; SCOTT et al., 2007; ZEGGINI et al., 2007; SAXENA et al., 2007; THE 
WELLCOME TRUST CASE CONTROL CONSORTIUM, 2007] in addition to the five 
gene regions that have been already identified by other approaches. Frayling reviewed 
above-mentioned GWASs and additional studies. He listed the best associations and 
showed that TCF7L2 has by far the best evidence and the biggest effect size regarding 
the risk of T2DM (Table 6) [FRAYLING, 2007b]. In 2008, another six loci with 
convincing evidence for T2DM involvement were published [ZEGGINI et al. 2008]. 
This GWAS boosted the number of gene regions involved in T2DM to the number of 
17.  
 
Table 6. 11 T2DM gene regions published 2007 
These gene regions were identified by GWASs published 2007 [SLADEK et al, 2007; 
STEINTHORSDOTTIR et al., 2007; SCOTT et al., 2007; ZEGGINI et al., 2007; 
SAXENA et al., 2007; THE WELLCOME TRUST CASE CONTROL 
CONSORTIUM, 2007] and additional studies [FRAYLING, 2007b] 
Example 
variant 
 
Closest 
gene 
Current 
evidence 
(P-value) 
Odds ratio 
(per allele) 
RAF 
(UK) 
 
N* 
rs10946398 CDKAL1 2×10–18 1.14 (1.11–1.17) 0.32 16,200 
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Example 
variant 
 
Closest 
gene 
Current 
evidence 
(P-value) 
Odds ratio 
(per allele) 
RAF 
(UK) 
 
N* 
rs10811661 CDKN2A–2B 8×10–15 1.20 (1.14–1.25) 0.83 12,400 
rs8050136 FTO 1×10–12 1.17 (1.12–1.22) 0.40 10,400 
rs1111875 HHEX–IDE 7×10-17 1.15 (1.10–1.19) 0.65 12,800 
rs4402960 IGF2BP2 9×10–16 1.14 (1.11–1.18) 0.32 16,200 
rs5215 
(E23K) 
KCNJ11 5×10–11 1.14 (1.10–1.19) 0.35 15,600 
rs1801282 
(P12A) 
PPARG 
 
2×10–6 1.14 (1.08–1.20) 0.87 >20,000 
rs13266634 SLC30A8 1×10–19 1.15 (1.12–1.19) 0.69 14,400 
rs4430796 TCF2 8×10–10 1.10 (1.07–1.14) 0.47 >20,000 
rs7901695 TCF7L2 1×10-48 1.37 (1.31–1.43) 0.31 2,760 
rs10010131 WFS1 1×10–7 1.11 (1.08–1.16) 0.60 >20,000 
*Total number of cases and controls needed in a 1:1 ratio to provide 80% power to 
detect an effect at P = 5 x 10-7, on the basis of UK risk allele frequencies and assuming 
a 5% disease frequency.  
[FRAYLING, 2007b] modified 
 
Figure 9. Effect sizes of the 11 T2DM gene regions published 2007  
These gene regions were identified by GWASs published 2007 [SLADEK et al, 2007; 
STEINTHORSDOTTIR et al., 2007; SCOTT et al., 2007; ZEGGINI et al., 2007; 
SAXENA et al., 2007; THE WELLCOME TRUST CASE CONTROL 
CONSORTIUM, 2007] and additional studies [FRAYLING, 2007b] 
 
[FRAYLING, 2007b] reproduced 
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CDKAL1 
Steinthorsdottir et al. performed a 3-stage GWAS in Icelandic individuals with T2DM 
(1,399 individuals with T2DM; 5,275 controls). The top signals were pursued in a fast-
tracking effort and so 47 SNPs were genotyped in 1,110 Danish T2DM cases and 2,272 
controls. Two SNPs (rs7756992 and rs13266634) were then chosen for a further 
investigation in three other T2DM case-control groups of European ancestry. They 
found that SNP rs7756992 within the cyclin-dependent kinase (CDK5) regulatory 
subunit associated protein 1-like 1 (CDKAL1) gene is associated with T2DM. Meta-
analysis of the five T2DM case-control studies showed that homozygous carriers of the 
risk allele G have a 1.50-fold (95% CI 1.31-1.72) increased risk and heterozygous 
carriers of the risk allele G have a 1.15-fold (95% CI 1.06-1.24) risk to develop T2DM. 
The allelic OR amounts to 1.20 (95% CI 1.13-1.27) [STEINTHORSDOTTIR et al., 
2007].  
Scott et al. showed that another SNP within CDKAL1 is associated with T2DM, namely 
rs7754840 (OR 1.12; 95% CI 1.08-1.16; P = 4.1 x 10-11). To note is that the results 
presented from Scott at al. are actually results from a meta-analysis, because most of the 
associations reached only significance when they pooled the data. Additional data came 
from the Diabetes Genetics Initiative (DGI) and the Wellcome Trust Case Control 
Consortium UKT2D United Kingdom T2D Genetics Consortium/United Kingdom T2D 
Genetics Consortium (WTCCC/UKT2D) [SCOTT et al., 2007]. 
The role of CDKAL1 is currently unknown, but it is speculated that the gene product 
has a role in the inhibition of the CDK5/p35 complex in pancreatic beta cells. The 
complex regulates the insulin gene expression, which is decreased when too much 
glucose is present (glucotoxicity). By inhibition of the complex, the insulin gene 
expression is not declined; the response to glucotoxicity is not impaired 
[STEINTHORSDOTTIR et al., 2007]. Expression of CDKAL1 mRNA can be found in 
human pancreatic islet and skeletal muscle [ZEGGINI et al., 2007]. Steinthorsdottir et 
al. showed, by the way, that rs7756992 is associated with a lower insulin response. 
Homozygous (GG) carriers of the risk allele showed significant 22 % lower corrected 
insulin response than noncarriers. In contrast, only 2 % of the heterozygous (AG) 
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carriers showed a nonsignificant lower corrected insulin response 
[STEINTHORSDOTTIR et al., 2007]. 
 
CDKN2A/B 
SNP rs10811661 within the cyclin-dependent kinase inhibitor 2A (CDKN2A/B) gene is 
associated with T2DM (OR 1.20; 95% CI 1.14-1.25; P = 7.8 x 10-15) as shown by Scott 
et al. all data (FUSION, DGI, and WTCCC/UKT2D) [SCOTT et al., 2007]. 
Grarup et al. confirmed the association with SNP rs10811661 by investigating 10,705 
Danish subjects. The candidate gene study was designed to validate and extent GWASs. 
The T-allele was associated with a 1.30-fold increased risk in an additive genetic model 
(OR 1.30 per risk allele; 95% CI 1.16–1.47; Padd
 = 1 x 10–5). Moreover, they showed 
that variations within CDKN2A/B loci are responsible for an impairment of glucose- 
and totbutamide-induced insulin release in middle-aged and young healthy individuals 
leading to the assumption that there is a dysfunction of the beta cells [GRARUP et al., 
2007].  
 
FTO 
Pooled data from FUSION, DGI, and WTCCC/UKT2D showed that the fatso/Fat mass 
and obesity associated (FTO) gene is associated with T2DM. Risk allele A of SNP 
rs8050136 increased the T2DM risk 1.17-fold (95% CI 1.12-1.22; P = 1.3 x 10-12) 
[SCOTT et al., 2007].  
As mentioned before data from the WTCCC was included in that meta-analysis. Results 
from this study alone provided evidence for an additional SNP within FTO. They 
showed that variant rs9939609 increases the T2DM risk 1.27-fold (95% CI 1.16-1.37; P 
= 5 x 10-8) [THE WELLCOME TRUST CASE CONTROL CONSORTIUM, 2007].  
This gene contributes to the T2DM risk through the mediation of obesity, because the 
association disappears when adjusted for BMI [ZEGGINI et al. 2007]. 
 
 
  
36 
IDE-HHEX-KIF11 
Two SNPs (rs1111875 and rs7923837) within chromosome 10 were identified by 
Sladek et al. to be associated with T2DM. Homozygous carriers of the risk allele A had 
an increased risk for T2DM in the range of 1.44-1.45; heterozygous carriers of the risk 
allele A had an increased risk for T2DM in the range of 1.19-1.22. Those SNPs are 
located in a LD block (Figure 8) that contains two genes potentially involved in beta 
cell development or function, namely the insulin-degrading enzyme (IDE) and the 
homeodomain protein HHEX – as well as kinesin-interacting factor 11 (KIF11) 
[SLADEK et al, 2007]. 
The association of one of those SNPs (rs1111875) was also confirmed by a meta-
analysis of three GWASs (FUSION, WTCCC/UKT2D, DGI) (OR 1.13; 95% CI 1.09-
1.17; P = 5.7 x 10-10) [SCOTT et al., 2007] and in a case-control study of 10,705 Danish 
subjects (OR 1.13 per allele; 95% CI 1.03–1.23; Padd
 = 0.008). This case-control study 
showed, moreover, that variations within the HHEX/KIF11/IDE are related to 
pancreatic beta cell dysfunctions by conferring an impairment of glucose- and 
totbutamide -induced insulin release in middle-aged and young healthy subjects 
[GRARUP et al., 2007]. 
It is to notice that likewise TCF7L2, HHEX is a target of the Wingless-type (Wnt) 
signalling pathway [SLADEK et al, 2007].  
 
IGF2BP2 
Scott et al. contributed to the identification of a T2DM-associated variant near the 
insulinlike growth factor 2 mRNA binding protein 2 (IGF2BP2) gene. All data 
(FUSION, DGI, and WTCCC/UKT2D) showed an association of SNP rs4402960 near 
IGF2BP2 with T2DM (OR 1.12; 95% CI 1.08-1.16; P = 4.1 x 10-11) [SCOTT et al., 
2007].  
The association of IGF2BP2 (rs4402960) with T2DM was replicated in a candidate 
gene study; the variant showed an association in a dominant genetic model (OR 1.17; 
95% CI 1.04–1.32; pdom = 0.01) [GRARUP et al., 2007].  
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Additionally, SNP rs1470579 within IGF2BP2 showed association with T2DM (OR 
1.17; 95% CI 1.11-1.23, P = 1.3 x 10-9). This was found by analysing DGI data 
[SAXENA et al. 2007].  
IGF2BP2 variants that predispose to diabetes may function by regulation of the IGF2 
translation. IGF2 is known as a member of the insulin family of polypeptide growth 
factors. It stimulates insulin secretion and is involved in the development and growth 
[SCOTT et al., 2007]. 
 
KCNJ11 
Pooled data from FUSION, DGI, and WTCCC/UKT2D showed that the potassium 
inwardly rectifying channel, subfamily J, member 11 (KCNJ11) gene is associated with 
T2DM. Risk allele T of SNP rs5219 increased the T2DM risk 1.14-fold (95% CI 1.10-
1.19; P = 6.7 x 10-11). The identified SNP rs5219 within KCNJ11 is a non-synonymous 
one (Glu23→Lys23). Another SNP (rs5215) is nearly in a perfect association (r2 = 
0.995) [SCOTT et al., 2008].  
KCNJ is a reasonable candidate gene for T2DM, because it encodes a component of a 
potassium channel with a key role in beta cell physiology; therefore, it is a target for 
anti-diabetic therapies [FRAYLING, 2007b]. 
 
PPARG 
SNP Pro12Ala is the most investigated SNP within the peroxisome proliferator-
activated receptor gamma (PPARG) gene. It is a non-synonymous SNP, which is the 
result of a CCA-to-GGA missense mutation [SOOKOIAN et al., 2005]. Although it is 
the most investigated, all data (FUSION, DGI, WTCCC/UKT2D) showed a strong, but 
not a genome-wide significant association, between SNP rs1801282 (Pro12Ala) and 
T2DM (OR 1.14; 95% CI 1.08-1.12; P = 1.7 x 10-6) [SCOTT et al., 2007]. 
Similar was shown by the GWAS of Zeggini et al. Indistinguishable from that signal at 
rs1801282 (Pro12Ala) was the signal at SNP rs17036101. Latter increased the risk of 
T2DM 1.15-fold (P = 2.0 x 10-7), but the prespecified threshold of P = 5.0 x 10–8 was 
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not met. Interestingly, the SNP was not convincingly associated with BMI or other 
T2DM related traits [ZEGGINI et al., 2008].  
In addition, a meta-analysis of candidate gene studies, which aimed to clear the question 
whether SNP Pro12Ala is truly associated with T2DM, showed no conclusive evidence. 
They analysed 41 published and 2 unpublished studies (all together 42,910 individuals 
from Asia, Europe, and North America) and showed that Ala12 carriers have a 19 % 
T2DM risk reduction. However, the observed association was highly heterogeneous (P 
= 0.005). This was partly explained by the BMI of the control group; the risk reduction 
was greater when the BMI was lower. Heterogeneity remained after stratifying 
according to the three different geographic regions (Asia, Europe, and North America) 
in the European subgroup (P = 0.02). Furthermore, they stratified the data from Europe 
according to a North-South gradient. This analysis showed that the risk reduction is 
bigger in North Europe (26 % reduction, P < 0.0001) than in Central Europe (10 %, P = 
0.04) and non-existing in South Europe (Table 7). The authors suggested that this result 
might be due to publication bias, because it is unlikely that negative results from 
Northern Europe have been published, but they included negative results from Italian 
studies [LUDOVICO et al., 2007].  
 
Table 7. Risk of T2DM according to PPARG Ala12 variant stratified by region 
Study OR (95 % CI) 
All Asians 0.65 (0.54-0.79) 
All Europeans 0.86 (0.79-0.95) 
All North-Europe (Scandinavians, British) 0.74 (0.66-0.83) 
All Central-Europe (Poles, Germans, French, Czechs) 0.90 (0.82-1.00) 
All South-Europe (Italians, Spaniards) 1.01 (0.80-1.28) 
All North Americans 0.82 (0.67-1.01) 
[LUDOVICO et al., 2007] modified 
 
Ludovico et al. assumed that the heterogeneous risk in Europe might be through 
different genetic and/or environmental background [LUDOVICO et al., 2007]. 
That the observed heterogeneity may partly be explained by physical activity was 
reported by a Finnish study. Increased physical activity decreased the effect of the risk 
alleles of rs17036314 and rs1801282 (Pro12Ala) on the conversion from IGT to T2DM. 
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After adjustment for baseline fasting glucose only SNP rs17036314 remained 
significantly associated [KILPELÄINEN et al., 2008]. 
PPARG belongs to the peroxisome proliferator-activated receptors (PPARs) family. 
These endogenous receptors for fatty acids and lipid metabolites modulate our rates of 
macronutrient oxidation, regulate the systemic inflammatory response, and improve 
systemic insulin sensitivity when a ligand binds. Furthermore, their activation inhibits 
the hypertrophy of adipocytes, which leads to insulin resistance via a decreased plasma 
adiponectin level [GURI et al., 2008].  
 
SLC30A8 
The non-synonymous SNP rs13266634 (Arg325→Trp325) [FRAYLING, 2007b] was 
repeatedly associated with T2DM [SLADEK et al., 2007; STEINTHORSOTTIR et al., 
2007; SCOTT et al., 2007]. This SNP is located within the solute carrier family 30 (zinc 
transporter), member 8 (SLC30A8) gene and was identified by Sladek et al. as the most 
significant SNP compared to the other newly associated SNPs. They found that 
homozygous (CC) individuals have a 1.53-fold increased risk and heterozygous (CT) 
individuals have a 1.18-fold increased risk to develop T2DM [SLADEK et al, 2007]. 
The GWAS conducted by Steinthorsdottir et al. showed smaller effect sizes of that SNP 
when analysing data from five T2DM case-control studies (replication sample). The CC 
type of SNP rs13266634 was associated with a 1.26-fold (95% CI 1.10-1.43) increased 
risk and the CT type was associated with a 1.05-fold (95% CI 0.93-1.19) increased risk. 
Every risk allele accounted for a 1.15-fold increased risk (allelic OR 1.15; 95% CI 1.08-
1.22; P = 7.7 x 10-9) [STEINTHORSDOTTIR et al., 2007].  
Pooled data from FUSION, DGI and WTCCC/UKT2D showed also that rs13266634 is 
associated with T2DM. Risk allele C increased T2DM risk 1.12-fold (OR 1.12; 95% CI 
1.07-1.16; P = 5.3 x 10-8). The association was even stronger when they adjusted for 
BMI (or waist circumferences). An adjustment for blood pressure variables showed no 
effect [SCOTT et al., 2007].  
The zinc transporter, which is encoded by SLC30A8, is solely found in pancreatic beta 
cells and is involved in the final stages of insulin biosynthesis. This is because of the 
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insulin co-crystallization with zinc [SLADEK et al, 2007]. A dysfunction of the 
transporter, through variation of SLC30A8, may affect zinc accumulation and 
subsequently alter insulin stability, storage, or secretion [SCOTT et al., 2007]. To 
mention is that Steinthorsdottir et al. observed a significant lower insulin response in 
individuals carrying the risk allele C [STEINTHORSDOTTIR et al., 2007]. 
 
TCF7L2 
The transcription factor 7-like 2 (TCF7L2) gene is the most important susceptibility 
gene for T2DM, because variants showed the best evidence and the biggest effect sizes 
in comparison to the other T2DM susceptibility genes (Table 6). 
Pooled data (FUSION, DGI and WTCCC/UKT2D) showed that the risk allele T of SNP 
rs7901695 increase the T2DM risk 1.37-fold (95% CI 1.31-1.43; P = 1 x 10-48) with an 
association even stronger after adjustment for BMI (or waist circumferences). 
Adjustment for blood pressure variables showed no effect [SCOTT et al., 2007].  
Sladek et al. related another SNP (rs7903146) within TCF7L2 to T2DM with 
homozygous carriers (TT) having a 2.77-increased risk and heterozygous carriers (CT) 
having a 1.65-increased risk to develop T2DM [SLADEK et al., 2007]. 
Steinthorsdottir et al. confirmed the association with SNP rs7903146 within TCF7L2 
(allelic OR 1.38; P = 1.82 x 10-10) [STEINTHORSDOTTIR et al., 2007]. 
However, the transcription factor 7-like 2 (TCF7L2) gene was already linked to T2DM 
by other gene association approaches. In 2006, researchers followed up a previously 
reported linkage of T2DM to chromosome 10q by using a high density of genotyped 
microsatellite markers. They identified an association of the composite allele X 
(microsatellite marker DG10S478X, nonzero alleles), within intron 3 of the TCF7L2 
gene, with T2DM in an Icelandic, in a Danish and in a US cohort. The combined RR 
from all cohorts (in each case individuals with T2DM and controls) was 1.56 (95% CI 
1.41-1.73) with a 4.7 x 10-18 P-value. To reach significance with the Bonferroni 
correction a P-value of 7.8 x 10-15 was needed. From the five investigated SNPs allele G 
of SNP rs12255372 showed the best, nearly perfect, association with DG10S478 
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(r2=0.95; P = 5.53 x 10-38). The SNP with the second best association was rs7903146 
(r2=0.78). Both were recommended for further research [GRANT et al. 2006].  
Zhang et al. confirmed the association of the TCF7L2 gene (rs12255372) with T2DM 
risk among Caucasians. Moreover, they pooled their data with data from Grant et al. All 
in all, they investigated 3,347 case and 3,947 control subjects. This meta-analysis 
showed that each copy of the T-allele was associated with a 1.48-fold (95% CI 1.37-
1.60; P < 10-16) increased risk for T2DM. The calculated OR for heterozygous carries 
(GT) was 1.42 (P = 5 x 10-10) and 2.11 for homozygous carriers (TT) (P < 10-16). The 
authors stated that they could not ascertain whether the rs12255372 SNP is a causative 
variant or a proxy for an underlying causal variant [ZHANG et al, 2006]. 
Interesting results came from the Finnish Diabetes Prevention Study (DPS), which 
investigated the association of SNPs rs12255372 and rs7903146 with incident T2DM. 
For one thing, they confirmed the association of rs12255372 again and for the other 
thing, they showed that lifestyle-interventions can reduce the risk conferred by genetic 
factors. 507 individuals with IGT, divided into an intensive diet and lifestyle 
intervention group (individually customized advice to reduce weight as well as total and 
saturated fat intake and individually customized advice to increase fibre intake and 
physical activity) or control group (general information on the benefits of weight 
reduction, physical activity and healthy diet), were included in that study. Remarkably, 
only the control group showed association between the TT genotype of rs12255372 and 
the risk of incident diabetes (HR 2.85; 95% CI 1.17-6.95, P = 0.021). No association 
was seen in the intervention group. SNP rs7903146 was not significantly associated 
with the risk of diabetes [WANG et al., 2007]. 
The exact mechanism by which the TCF7L2 gene is related to T2DM is not known yet. 
Data indicates that the regulating of glucagon-like peptide 1 (GLP-1) through the Wnt 
signalling pathway, which is one of the key developmental and growth regulatory 
mechanisms of the cell, is to consider. GLP-1 is an insulinotropic hormone that can 
lower blood glucose levels through several pathways e.g. stimulation of insulin 
secretion and biosynthesis [ZHANG et al, 2006]. Interestingly, the above-mentioned 
Finnish study showed that the T allele of rs12255372 within TCF7L2 is significantly 
associated with decreased insulin secretion [WANG et al., 2007]. 
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Genes associated with type 2 diabetes mellitus published in 2008 
Zeggini et al. carried out a meta-analysis of the DGI, FUSION, and WTCCC (all in all 
10,128 samples; 4,549 cases and 5,579 controls) data and enlarged SNP coverage by 
including untyped SNPs (based on HapMap) to identify additional, to the already 
published, associated SNPs. This meta-analysis was followed by a 2-stage study 
including 53,975 individuals. On the basis of the combined stage 1-3 analyses six 
additional SNPs showed evidence for association with T2DM (padd = 5.0 x 10
-8). SNPs 
near the genes JAZF1, THADA, ADAMTS, NOTCH2 and between genes CDC123 and 
CAMK1D as well as between TSPAN 8 and LGR5 belonged to the significant SNPs. 
ORs ranged from 1.09 to 1.15. None of the SNPs was convincingly associated with 
BMI or other T2DM-related traits [ZEGGINI et al., 2008].  
  
Table 8. Six T2DM gene regions published 2008 
These gene regions were identified by one GWAS published 2008. All data (Stage 1-
Stage 3) presented [ZEGGINI et al., 2008]  
SNP Nearest gene Chr Odds ratio (95%CI) P-value 
rs4607103 ADAMTS9 3 1.09 (1.06-1.12) 1.2x10-08 
rs12779790 CDC123, 
CAMK1D 
10 1.11 (1.07-1.14) 1.2x10-10 
rs864745 JAZF1 7 1.10 (1.07-1.13) 5.0x10-14 
rs10923931 NOTCH2 1 1.13 (1.08-1.17) 4.1x10-08 
rs7578597 THADA 2 1.15 (1.10-1.20) 1.1x10-09 
rs7961581 TSPAN8, LGR5 12 1.09 (1.06-1.12) 1.1x10-09 
ADAMTS9 a disintegrin-like and metalloproteinase with thrombospondin type 1 
motif, 9; CDC123 cell division cycle protein 123 homolog; CAMK1D 
calcium/calmodulin-dependent protein kinase i-delta; JAZF1 juxtaposed with another 
zinc finger gene 1; NOTCH2 notch, drosophila, homolog of, 2; THADA thyroid 
adenoma-associated gene; TSPAN8 tetraspanin 8; LGR5 leucine-rich repeat-
containing G protein-coupled receptor 5 
[ZEGGINI et al., 2008] modified 
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Genes associated with fasting plasma glucose 
Two GWASs were published in 2008 that found a new gene association for fasting 
plasma glucose (FPG) [CHEN et al., 2008; BOUATIA-NAJI et al., 2008]. 
 
G6PC2 
Variants located between the genes glucose-6 phosphatase catalytic subunit 2 (G6PC2) 
and ATP-binding cassette, sub-family B (MDR/TAP), member 11 (ABCB11) showed 
significant association with fasting glucose concentration in two genome wide scans 
including a total of 5,088 nondiabetic individuals from Finland and Sardinia. The 
significance remained after adjustment for BMI, leading to the assumption that the main 
contribution to the observed association is not mediated by obesity. Anyhow, the found 
associations were then partly replicated in additional 18,436 nondiabetic individuals of 
mixed European decent. Pooled data from all studies (n = 24,046) showed that rs563694 
(SNP with the strongest association within gene G6PC2) is associated with FPG by a p-
value of 6.4 x 10-33. Across these studies, each copy of the SNP rs563694 major allele 
increased the fasting glucose concentration by 0.01-0.16mM. This amounts to an 
approximately 1% contribution to the total variation observed in fasting glucose. 
Interestingly, no association was observed between fasting glucose and SNP rs563694 
and rs560887 in individuals with T2DM [CHEN et al., 2008]. 
In contrast to Chen et al., Bouatia-Naji et al. observed the strongest association between 
rs560887 and fasting plasma glucose. Anyhow, SNP rs560887 is in high LD with SNP 
rs563694 (D´ = 0.99, r2 = 0.84), but opposite to rs563694, rs560887 is not located in 
between two genes, it is located directly in intron 3 of G6PC2. Interestingly, the seen 
association was, like the association in the former study, independent of BMI. 654 
normoglycemic participants were investigated in that GWAS followed by an 
investigation of three independent populations (n = 9,353). The overall meta-analysis of 
the replication samples showed that each copy of the A allele results in a 0.06 mmol/l 
FPG decrease (combined P = 4 × 10-23) and is associated with pancreatic beta cell 
function (HOMA-B model, combined P = 3 × 10-13). In addition, the interaction of 
rs560887 with SNPs formally associated with FPG, namely GCK (rs1799884) and 
GCKR (rs1260326), was investigated. They observed that these three SNPs have an 
  
44 
additive effect on FPG (P = 5 x 10-21). Carriers of more than four alleles related to low 
FPG showed a mean 0.24 mmol/l (4.5%) decrease of FPG compared with those 
individuals carrying only one allele (Figure 10). Remarkably, no association of a SNP 
within G6PC2 and T2DM risk was observed. The authors suggested that the genetic 
determinants that regulate FPG might be different from those that predispose somebody 
to T2DM [BOUATIA-NAJI et al., 2008]. 
The protein encoded by G6PC2, also known as islet-specific glucose-6 phosphatase 
related protein (IGRP), is involved in the glucose metabolism, more precisely, the 
protein is involved in the gluconeogenic and glycogenolytic pathways. The mainly in 
the liver expressed gene ABCB11 is involved in the secretion of bile salts [CHEN et al., 
2008]. 
 
Figure 10. Combined effects of gene variants on FPG levels  
Combined effects of rs560887 (G6PC2), rs1260326 (GCKR), and rs1799884 (GCK) 
variants on FPG levels. Data are presented as mean [95% CI], and the P-value is for the 
beta coefficient in the linear regression model (adjusted for age, sex, and BMI) of FPG 
levels on the number of alleles associated with low FPG  
 
[BOUATIA-NAJI et al., 2008] reproduced 
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Genes associated with the homeostasis model assessment of insulin resistance 
MC4R 
In 2008, a GWAS was published, which investigated IR and related phenotypes in 
individuals from the UK of Indian Asian or European ancestry. They showed that the 
SNPs rs12970134, rs477181, rs502933 and rs4450508 within the melanocortin 4 
receptor (MC4R) gene are significantly associated with WC, HOMA-IR, WHR, weight, 
BMI and MetSyn (Table 9) in the population of Indian Asian ancestry and in the 
combined analysis. SNP rs12970134 was, for example, associated with HOMA-IR % 
by an effect size of 5.17 (95% CI 2.96-7.42; P = 3.2 x 10-6). Analysis of the European 
ancestry population was not significant. Multiple rare mutations of the MC4R gene 
cause hyperphagia and subsequently severe childhood obesity. Furthermore, they are 
associated with increased insulin levels. MC4R is, therefore, an interesting candidate 
gene when investigating the genetic determinants of IR [CHAMBERS et al., 2008]. 
 
Table 9. Association of a variant near MC4R with IR and related phenotypes  
Data is shown for SNP rs12970134 allele A in stage 2 participants 
 
 Indian Asian ancestry 
(n = 7,394) 
European ancestry 
(n = 4,561) 
All stage 2 participants 
(n = 1,955) 
HT p 
 Effect size or 
OR (95% CI) 
P Effect size or 
OR (95% CI) 
p Effect size or 
OR (95% CI) 
p  
HOMA-
IR (%) 
 
5.39  
(2.78-8.07) 
4.2 x 10-5 
 
5.16  
(1.18-9.29) 
0.01 5.17  
(2.96-7.42) 
3.2 x 10-6 0.95 
Waist-
hip ratio  
0.004  
(0.002-0.006) 
9.8 x 10-4 0.004 
(0.000-0.007) 
0.02 0.004  
(0.002-0.006) 
7.7 x 10-5 0.87 
Weight 
(kg)  
0.82 
(0.40-1.24) 
4.2 x 10-5 1.21  
(0.48-1.94) 
0.001 0.93 
 (0.56-1.31) 
1.0 x 10-6 0.37 
BMI 
(kg/m2) 
0.25  
(0.10-0.39) 
1.3 x 10-4 0.28  
(0.05-0.51) 
0.02 0.25 
(0.13-0.38)  
6.4 x 10-5 0.86 
MetSyn 1.13  
(1.05-1.21) 
0.002 1.13  
(1.00-1.27) 
0.01 1.12 
(1.06-1.20) 
2.3 x 10-4 0.93 
HT Heterogeneity 
Effect sizes or OR under an additive genetic model, with adjustment for age, gender and 
ethnic group in stage 2 and in the combined analysis. Statistical significance was given 
with a P-value of P < 0.006 after Bonferroni correction for nine phenotypes tested.  
[CHAMBERS et al., 2008] modified 
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2.7.2  Obesity  
As shown before FTO is related to T2DM through the altering of BMI, but this gene is 
not the only gene that was found to be associated with obesity traits. GWASs reported a 
vast number of – not always genome-wide significant – associated genes [FRAYLING 
et al., 2007a; LOOS et al., 2008; CHAMBERS et al., 2008; FOX et al., 2007]. The most 
important of them are listed and described (Table 10). The basic paradigm for a genetic 
predisposition to obesity is shown in Figure 12, located at the end of that chapter. 
  
Table 10. Eight gene regions associated with overweight/obesity or related traits 
identified by GWAS 
Gene regions associated with overweight/obesity or related traits identified by GWASs 
[FRAYLING et al., 2007a; LOOS et al., 2008; CHAMBERS et al., 2008; FOX et al., 
2007]. Because additional evidence from candidate gene studies or a CRP-GWAS 
[RIDKER et al., 2007] exists, even genes that didn´t reach the genome-wide 
significance are presented. 
Closest gene BMI Weight WHR WC FM OV OB 
ADIPOQ*    x    
CTNNBL1 x    x  x 
FTO x x x x x x x 
IL6R*    x    
INSIG2* x       
LEPR*    x    
MC4R x x   x x x 
PPARG* x   x    
*reached not the genome-wide significance 
BMI Body mass index; WHR waist to hip ratio; WC waist circumference; FM fat mass; 
OV overweight; OB obesity 
 
ADIPOQ 
The Adiponectin, C1Q and Collagen Domain Containing (ADIPOQ) gene is one of the 
genes with former evidence for association, but no genome-wide significant association 
has yet been observed. 
In the Framingham Heart Study-GWAS (100 k project; n = 1,341) it was reported that 
SNP rs1042464 is related to mean WC. Association was given for the family based 
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association test with a P-value of 0.024. To notice is that this finding reached not the 
required genome-wide significance [FOX et al., 2007]. 
In humans, the level of plasma adiponectin is inversely associated with BMI and body 
fat mass; loosing weight increases plasma adiponectin levels [SONG et al., 2006].  
 
CTNNBL1 
Opposite to the following studies a genome-wide association scan for obesity 
(examining approximately 500,000 SNPs) in a sample of 1,000 unrelated U.S. 
Caucasians provided no evidence for the FTO association, in contrast, they identified a 
novel gene, the catenin, beta like 1 (CTNNBL1) gene, which showed association with 
BMI and fat mass. The T allele of the most significant SNP rs6013029 was associated 
with a fat mass increase of 5.96 kg ( P-value of 2.7 x 10-7) and with a BMI increase of 
2.67 kg/m2 (P-value of 5 x 10-8). In a second stage they genotyped the most significant 
variants within CTNNBL1 in a case-control sample (n = 3,812). They repeated the 
association and showed that homozygous TT carriers have an increased risk of obesity 
(OR = 1.42) compared to homozygous GG carriers. The exact implication mechanism 
of CTNNBL1 is not known yet; however, as the protein structure of CTNNBLI is 
homolog to the beta-catenin structure, the function may be similar. Beta-Catenin is 
involved in the regulation of the adipogenic gene expression [LIU et al., 2008]. 
 
FTO 
Frayling et al. investigated the T2DM susceptibility gene FTO in a meta-analysis of 13 
cohorts with 38,759 participants (population-based studies and T2DM case and control 
studies including WTCCC data) further. They found an additive association of the 
variant rs9939609 with BMI. The analysis of the pooled data (population-based studies 
only) showed that each additional copy of the rs9939609 A allele was associated with a 
BMI increase of a mean of 0.10 Z-score units (95% CI 0.08-0.12; P = 2 x 10-20, 
equivalent to ~ 0.4 kg/m2). Moreover, rs9939609 A allele was associated with higher 
weight (overall per-A allele increase = 0.09 Z-sore units; 95% CI = 0.07–0.11; P = 4 x 
10-17; equivalent to ~ 1.2 kg) and higher WC (overall per-A allele = 0.08 Z-score units; 
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95% CI = 0.05-0.11; P = 4 x 10-9; ~ 1 cm). In a meta-analysis of all studies, 
homozygous risk carriers (AA; 16% of the population) were at increased risk of being 
overweight (OR = 1.38; 95% CI =1.26-1.52; P = 4 x 10-4) or obese (OR =1.67; 95% CI 
1.47-1.89; P = 1 x 10-14) compared with those individuals homozygous for the low-risk 
T allele (37% of the population). The SNP rs9939609 explained ~1% of BMI variance. 
In addition, they found that the variant contributes to childhood obesity [FRAYLING et 
al., 2007a]. 
Another variant (SNP rs1121980) was reported to be associated with obesity traits in the 
GWAS conducted by Loos et al. They showed by meta-analysis of four European 
population-based studies and three disease-case studies that the per allele effect for 
rs1121980 is equivalent to 0.27 kg m-2 (beta = 0.060; 95% CI 0.039-0.082 Z-score 
units; P = 3.6 x 10-8). Z-score units have been defined as “log10- transformed BMI, 
standardized by gender and age” [LOOS et al., 2008]. 
SNP rs1121980 was also associated with childhood obesity and severe adult obesity 
(2,900 cases and 5,100 controls). The T allele of SNP rs1121980 was strongly 
associated with severe adult obesity (OR = 1.55; 95% CI 1.39-1.73; P = 5.3 x 10-16). 
Furthermore, rs1421085 and rs17817449, potentially functional SNPs, showed 
associations [DINA et al., 2007].  
Do et al. aimed to investigate the mechanism by which the FTO variants (rs17817449, 
rs1421085) influence obesity traits; therefore, they genotyped 908 participants of the 
Quebec Family Study. SNP rs17817449 was associated either under an recessive model 
or an additive model with anthropometric parameters of obesity (weight, BMI, FM, 
waist and hip circumferences, WHR, percentage body fat and skinfold thickness), but 
also with fasting insulin, HOMA-IR, an insulin sensitivity index derived from an oral 
glucose tolerance test, resting metabolic rate and plasma leptin levels. The association 
with insulin sensitivity, resting metabolic rate, and plasma leptin levels disappeared 
when they adjusted for BMI. To note is that SNPs rs9939609, rs17817449, rs3751812, 
rs1421085 and rs8050136 are all in strong LD (r2 from 0.92 to 1) [DO et al., 2008]. 
The contribution of the FTO gene to the development of obesity might be mediated by 
the encoded 2-oxoglutarate-dependent nucleic acid demethylase. This enzyme is most 
frequently present in the hypothalamus [AL-ATTAR et al., 2008]. 
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IL6R 
Although no genome-wide significance was shown for an association of the interleukin 
6 receptor (IL6R) gene with obesity, this gene is mentioned, because another GWAS, 
which investigated CRP, showed genome-wide significant association [RIDKER et al., 
2008]. Anyhow, Fox et al. showed by the family based association test that SNP 
rs4129267 within IL6R is related to mean WC (P-value of 0.003) [FOX et al., 2007]. 
This gene encodes for a protein that is a subunit of the IL6 receptor complex. Variations 
in IL6R may lead to dysfunction of IL6, a cytokine that regulates cell growth and 
differentiation; furthermore, it plays an important role in immune response [NCBI, 
2008b]. 
 
INSIG 
Hinney et al. reviewed the latest findings regarding gene-obesity associations. They 
stated that the insulin-induced gene 2 (INSIG2) showed positive data, but this was not 
reliably replicable by now [HINNEY and HEBEBRAND, 2008]. Interestingly Fox et al. 
showed that five SNPs within INSIG2 are related to mean BMI. Significance, but not 
genome-wide significance, was given by the additive generalized estimating equations 
with P-values from 0.001 to 0.035 [FOX et al., 2007]. 
The protein that is encoded by INSIG2 inhibits the synthesis of cholesterol and fatty 
acid [SOOKOIAN and PIROLA, 2007].  
 
LEPR 
The same situation that is true for the IL6R gene is true for the leptin receptor (LEPR) 
gene. Only Fox et al. showed, by the additive generalized estimation equations, that the 
SNP rs2025804 within LEPR is related to mean WC, but the association is not a 
genome-wide significant one [FOX et al., 2007]. 
LEPR is a single-transmembrane-domain receptor of the cytokine receptor family. 
Through that receptor operates leptin, an adipocyte-specific hormone that regulates 
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adipose-tissue mass through hypothalamic effects on energy expenditure and satiety 
[NCBI, 2008b]. 
 
MC4R 
Additional to the SNP within the FTO gene there is substantial evidence that variants 
within the melanocortin-4 receptor (MC4R) gene have an effect on body weight. Two 
recently published GWASs showed associations between MC4R variants and obesity 
[LOOS et al., 2008; CHAMBERS et al., 2008]. 
Loos et al. reported that SNP 17782313 near MC4R is associated with fat mass, weight, 
and risk of obesity. The large-scale GWAS (n = 16,876) in individuals phenotyped for 
adult BMI was followed by replication studies (n = 66,340). Meta-analysis of all studies 
showed a BMI association in adults (per-allele effect for rs17782313C = 0.049; 95% CI 
0.037-0.061 Z-score units; P = 2.8 x 10-15; equivalent to 0.22 kg m-2) and a BMI 
association in children aged 7-11 (per-allele effect for rs17782313C = 0.13, Z-score 
units; P = 1.5 x 10-8). The association with BMI was mediated through weight (per-
allele effect for rs17782313C = 0.059; 95% CI 0.047-0.071 Z-score units; P = 2.8 x 10-
15; equivalent to ~760g) and height (per-allele effect = 0.030; 95% CI 0.018-0.042 Z-
score units; P = 8.7 x 10-7; equivalent to ~0.21 cm) in adults, but only through weight in 
children. Adults had an increased risk of overweight (OR = 1.08; P = 1.6 x 10-9) as well 
as an increased risk of obesity (OR = 1.12; P = 5.2 x 10-9) when carrying an 
rs17782313C allele. Anyhow, it is to notice that the contribution to the observed 
variance is rather small. The identified SNPs near MC4R account for ~0.14% variance 
in adult BMI and ~0.26% variance in fat mass at age 9. In addition to the already stated 
results, they found an additive effect on BMI that was attributed to FTO variants as well 
as MC4R variants (Figure 11) and reported that genetic determinants of monogenic and 
multifactorial forms of the same condition can overlap. Latter was found, because the 
same SNP, which was associated with obesity in the population-based studies, was also 
associated in populations with severe early onset obesity. SNP rs17782313 increased 
the risk of extreme obesity 1.30-fold (95% CI 1.20-1.42; P = 8.0 x 10-10) [LOOS et al., 
2008]. 
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Figure 11. Additive effect of FTO variants and MC4R variants 
Association between the combined SNPs (rs17782313, rs1121980) and BMI in adults 
and association between the combined SNPs (rs17782313, rs9939609) and BMI in 
children. BMI difference amounts to 0.26 Z-score units (or ~ 1.17 kg m-2) in adults and 
0.56 Z-score units in children when comparing individuals with no risk alleles at either 
locus (19% of the population) with those homozygous at both (1% of the population). 
 
 
[LOOS et al., 2008] reproduced 
 
Chambers et al., showed in their 2-stage GWAS of IR and related phenotypes in a 
population cohort of individuals from the UK of Indian Asian or European ancestry that 
the strongest association with WC was near the MC4R gene with rs12970134, followed 
by rs471181, rs502933, rs4450508. All of those SNPs are in high LD (r2 = > 0.5) on 
chromosome 18. Three of the four SNPs reached genome-wide significance when a 
combined analysis of stage one and two data (Indian Asians and European ancestry) 
was done. The effect size for the association of rs12970134 risk allele A with WC under 
an additive genetic model adjusted for age, sex, and ethnicity was 0.88 cm (95% CI 
0.59-1.17; P = 1.7 x 10-9). Moreover, SNP rs12970134 was significantly associated with 
WHR, weight, and BMI but only in the population of Indian Asian ancestry and in the 
combined analysis of all stage 2 participants (Indian Asian ancestry and European 
ancestry) (Table 9). Variant V103I was uncommon in that study (MAF 0.6%) and not in 
a LD with any of the mentioned SNPs [CHAMBERS et al. 2008]. 
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The above-mentioned variant V103I was the first confirmed polygenetic variant that 
was associated with BMI with a higher frequency of Val103 in obese individuals. The 
effect size of the 103Ile allele on mean BMI was stated with -0.5 kg/m-2 [HINNEY and 
HEBEBRAND, 2008].  
The association between V103I and risk of obesity was investigated by three UK 
population based cohort studies (n = 8,304 in total) that were followed by a meta-
analysis of 29,563 individuals. The non-synonymous Val103Ile (rs2229616) 
polymorphism showed a protective function against human obesity. Carriers of the 103I 
allele had an 18% (95% CI 4–30%; P = 0.015) lower risk of obesity compared with non-
carriers [YOUNG et al., 2007].  
MC4R is a plausible biological candidate for the association with obesity, because rare 
MC4R mutations are associated with hyperphagia and severe childhood obesity 
[CHAMBERS et al., 2008]. However, evidence for the mechanism relating the found 
variants to MC4R expression is missing [LOOS et al., 2008].  
 
PPARG 
In a GWAS (Framingham Heart Study 100 k project; n = 1,341), six SNPs (rs2938392, 
rs709157, rs10510422, rs10510423, rs2454431, rs963163) within the PPARG gene 
were found to be related to mean BMI and mean WC. Significance, but not genome-
wide significance, was either given for the family based association test or the additive 
generalized estimation equations. The P-values ranged from 0.003 to 0.047. An 
association of the SNP rs1801282 (Pro12Ala) with mean BMI or mean WC was not 
found [FOX et al., 2007]. 
As mentioned before, the Ala allele of the variant Pro12Ala (rs1801282) within the 
PPARG gene is seen as protective against T2DM [SCOTT et al., 2007]. Anyhow, a 
population-based study of 934 high-school students of Caucasian origin showed that 
there is no association between IR, BMI and leptin levels and PPARG genotypes. They 
found instead that the 12Ala variant is significantly associated with an increased WHR 
in normotensive subjects (OR = 2.37; 95% CI 1.05-5.33, P < 0.03), independently of 
age, sex, hypertension, plasma leptin, or IR [SOOKOIAN et al., 2005]. 
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Additional susceptibility genes found by GWAS 
The above-described genes are associated with obesity; however, there are many more 
susceptibility genes identified by at least Fox et al. This GWAS reported a vast number 
of associated genes. Some of them previously associated with obesity, some of them 
newly associated. The SSTR2 (somatostatin receptor 2) gene, the LRP1B (low density 
lipoprotein receptor-related protein 1b) gene, the VIP (vasoactive intestinal peptide) 
gene and the ESR1 Xba (estrogen receptor 1) gene are for instance under the identified 
associated genes. However, they found the best association with mean BMI and mean 
WC by generalized estimating equations with the intergenic SNP rs110683 (P = 1.22 x 
10-7) and with the SNP rs4471028 (P = 1.96 x 10-7) near to GDAP1 (ganglioside-
induced differentiation-associated protein 1) gene. To notice is that none of the 
associated SNPs reached genome-wide significance [FOX et al., 2007]. For that reason 
only the genes with additional evidence are discussed. For further details, cf. Fox et al.  
 
 
Figure 12. Basic paradigm for a genetic predisposition to obesity 
 
 
Source: http://www.pbrc.edu/huec7005/slides/bouchard.ppt 
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2.7.3  Dyslipidemia 
In the last two years, GWASs confirmed gene associations and identified newly 
associated genes or new gene variants within confirmed associated genes, which are 
implicated in the individual variation of lipid concentrations. The number of associated 
genes and gene variants was, therefore, growing. To illustrate the point, Willer et al. 
identified more than 25 independent common variants, which are significantly 
associated with lipid concentrations (P < 5 x 10-8) [WILLER et al., 2008]. 
The authors of the reviewed GWASs mostly distinguished between a newly associated 
gene and an already known associated gene. For that reason this part of this review is 
also split up, in already known associated genes and newly associated genes. 
 
Already known associated genes 
Table 11. Ten previously in lipid concentrations implicated gene regions 
Previously in lipid concentration implicated genes successfully replicated by GWAS 
[KOONER et al., 2008; KATHIRESAN et al, 2008; WILLER et al., 2008; SAXENA et 
al. 2007] and associated traits 
Closest gene(s) Associated trait 
 LDL-C HDL-C TG additional 
ABCA1  x   
APOA1-APOC3-
APOA4-APOA5 
 x x  
APOB x  x apoB 
APOE cluster x    
CETP  x  apoA-I 
LDLR x    
LIPC  x x  
LIPG  x   
LPL  x x  
PCSK9 x    
 
 
ABCA1 
Kathiresan et al. found that SNP rs3890182 within the ATB-Binding cassette, subfamily 
A, member 1 (ABCA1) gene is associated with HDL-C (P = 3 x 10-10) when carrying 
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out a meta-analysis of one GWA and three replication studies [KATHIRESAN et al., 
2008]. 
Willer et al. also showed association between a variant within ABCA1 and HDL-C. 
Rs4149268 was associated by a two-sided P-value of 1.2 x 10-10 in the combined stage 1 
and stage 2 analysis. Allele C at rs4149268 increased TG concentration by 0.82 mg/dl. 
ABCA1 encodes a protein that is a known transporter of cholesterol [WILLER et al., 
2008]. 
 
APOA1-APOC3-APOA4-APOA5  
As shown in the GWAS conducted by Saxena et al., apolipoprotein A5 (APOA5) is 
associated with the TG level (SNP rs481843; P = 3.3 x 10-5) in Europeans [SAXENA et 
al., 2007].  
Kooner et al. carried out two genome-wide associations scans. One GWAS was in 1,005 
European men and one in 1,006 Indian Asian men aged 35-65 years ascertained on 
NCEP-ATPIII criteria for MetSyn. The genomes scan in the Indian Asian population 
showed that SNP rs1558861 and rs17120139 are significantly related to TG levels (P = 
3.8 x 10-5 and P = 0.011, respectively, after Bonferroni correction). Those SNPs are 
located in the vicinity of the APOA1-APOC3-APOA4-APOA5 associated cluster. Stage 
2 and stage 3 results also confirmed associations with variants near the cluster and TG 
concentration. To notice is that stage 2 investigated partly individuals of European 
ancestry and stage 3 investigated only individuals of European ancestry [KOONER et 
al., 2008]. 
Another SNP near the cluster (rs28927680) was found to be associated with HDL-C (P 
= 2 x 10-5) and TG-levels (P = 2 x 10-17) when carrying out a meta-analysis of one 
GWA and three replication studies. To notice is that the prespecified significance level 
was 5 x 10-8, the HDL-C association is, therefore, not genome-wide significant 
[KATHIRESAN et al., 2008]. 
Willer et al. also showed association between variants within APOA1-APOC3-APOA4-
APOA5 gene cluster and TG level. Rs12286037 was associated by a two-sided P-value 
of 1.0 x 10-26 and rs662799 was associated by a two-sided P-value of 2.4 x 10-15 in the 
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combined stage 1 and stage 2 analysis. To note is that SNP rs12286037 accounted for 
the biggest effect size (25.82 mg/dl) compared to the other SNPs associated with TG 
concentration [WILLER et al., 2008]. 
 
APOB 
A GWAS of five study populations consisting of up to 11,685 participants showed a 
significant association (P < 1.0 x 10-7) between apolipoprotein B (APOB) SNPs and 
concentrations of LDL-C. Within the APO B variants, SNP rs562338 accounted for the 
biggest effect size (change in LDL-cholesterol concentration per additional minor allele 
beta = -0.04, SE 0.01; P = 1.4 x 10-9). However, there was substantial evidence for 
heterogeneity between studies after adjustment for multiple testing. The same 
researchers conducted another GWAS in three UK study populations consisting of up to 
4,337 participants. This GWAS showed significant association of a different APOB 
variant (rs1713222) with LDL-C concentrations (change in LDL-cholesterol 
concentration per additional minor allele beta = -0.17, SE 0.03, P = 1.0 x 10-8). This 
time there was no heterogeneity between the study populations [SANDHU et al., 2008]. 
Kathiresan et al. confirmed that variants within APOB influence LDL-levels and TG-
levels when analysing pooled data form the DGI-GWAS and three replication studies. 
Variant rs693 was significantly associated with LDL-C (P = 1 x 10-60) and TG (P = 2 x 
10-7) [KATHIRESAN et al. 2008].  
Variant rs693 was also associated with LDL-C in the GWAS conducted by Saxena et al. 
(P = 7.1 x 10-7). Moreover, they found an association between that SNP and apoB (P = 
9.4 x 10-5) [SAXENA et al., 2007]. 
Willer et al. reported additionally evidence for the association between the variant rs693 
and LDL-C. The SNP was associated by a two-sided P-value of 3.1 x 10-9 in the 
combined stage 1 and stage 2 analysis. Furthermore, SNPs rs562338 (two-sided P-value 
5.6 x 10-22) and rs754523 (two-sided P-value 8.3 x 10-12) showed associations. 
Apolipoproteins are encoded by APOB [WILLER et al., 2008]. 
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APOE and APOE-APOC cluster 
Kathiresan et al. confirmed the association of the apolipoprotein E (APOE) gene and 
blood lipids. They showed that variant rs4420638 within APOE-C1-C4-C2 is 
significantly related to LDL-C (P = 1 x 10-60) when they analysed pooled data from the 
DGI-GWAS and three replication studies [KATHIRESAN et al., 2008].  
SNP rs4420638 was also reported to be significantly associated with LDL-C in the 
GWAS conducted by Saxena et al. (P = 3.4 x 10-13) [SAXENA et al., 2007] and in the 
GWAS conducted by Willer et al. (two-sided P = 3.0 x 10-43). Additionally, SNP 
rs10402271 near APOE/C1/C4 was found to be associated with LDL-C (two-sided P = 
1.2 x 10-9) in the combined stage 1 and stage 2 analysis [WILLER et al., 2008]. 
 
CETP 
Kooner et al. reported that five SNPs (rs711752, rs5882, rs1800777, rs5880, rs7205804) 
in or around the cholesteryl ester transfer protein, plasma (CETP) gene are significantly 
associated with HDL-C (P < 7 x 10-5 after Bonferroni correction) in the combined 
analysis of stage 2 and stage 3. Interestingly, SNP rs711752 within CETP was also 
associated in the initial scan conducted in 1,005 Northern Europeans men who were 
diagnosed with the MetSyn defined by the NCEP-ATPIII criteria (P = 7.2 x 10-5 after 
correction for 216,774 tests) [KOONER et al., 2008]. 
Kathiresan et al. replicated the association with SNP rs1800775. They found that this 
SNP is associated with HDL-C (P = 1 x 10-73) by carrying out a meta-analysis of one 
GWAS and three replication studies [KATHIRESAN et al., 2008]. 
Saxena et al. also identified an association of SNP rs1800775 with HDL-C (P = 2.5 x 
10-13). Moreover, an association of that variant with another lipoprotein trait, namely 
apoA-I (P = 2.7 x 10-6) was shown [SAXENA et al., 2007]. 
Willer et al. identified five SNPs (rs3764261, rs1864163, rs9989419, rs12596776, 
rs1566439), all of them not mentioned before, to be associated with HDL-C when 
analysing the combined stage 1 and stage 2 data. SNP rs3764261 was the most 
significant of them (P = 2.3 x 10-57). Interestingly, SNP rs1864163 was the variant with 
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the biggest effect size (4.12 mg/dl) in comparison to the other SNPs associated with 
HDL-C. A transporter for cholesterol ester is encoded by CETP [WILLER et al., 2008]. 
 
LDLR 
A GWAS of three UK study populations consisting of up to 4,337 participants showed 
significant association of LDL-C receptor (LDLR) variants (rs2228671, rs11668477) 
with LDL-C concentrations (change in LDL-cholesterol concentration per additional 
minor allele beta = -0.18, SE 0.03, P = 1.1 x 10-8 and beta = -0.15, SE 0.03, P = 1.5 x 
10-8, respectively) [SANDHU et al., 2008]. 
In the GWAS conducted by Kathiresan et al., another SNP within LDLR was found to 
be associated with LDL-C. The combined analysis of the DGI-GWAS and three 
replication studies showed that rs6511720 is strongly related to LDL-C (P = 2 x 10-51). 
In one of the replication studies, the Malmö Diet and Cancer Study, LDL-C values 
varied by ~ 7 mg/dl per copy of the minor allele at rs6511720 [KATHIRESAN et al., 
2008]. 
Interestingly, Willer et al also reported an association of SNP rs6511720. The variant 
accounted for the best effect size (9.17 mg/dl) within the SNPs associated with LDL-C 
in the combined stage 1 and stage 2 analysis (two-sided P-value of 4.2 x 10-26) 
[WILLER et al., 2008]. 
 
LIPC 
SNP rs1800588 within the lipase, hepatic (LIPC) gene was found to be associated with 
HDL-C (P = 2 x 10-32) when carrying out a meta-analysis of one GWAS and three 
replication studies [KATHIRESAN et al., 2008]. 
Saxena et al. showed that another variant within LIPC, namely rs261332, is associated 
with HDL-C (P = 3.4 x 10-5) [SAXENA et al.2007].  
That variant (rs261332) was also found to be strongly associated with HDL-C (two-
sided P-value 3.2 x 10-20) in the combined stage 1 and stage 2 analysis of the GWASs 
conducted by Willer et al. Furthermore, they reported rs4775041 to be associated with 
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HDL-C (two-sided P-value 2.3 x 10-15) and to be associated with TG (two-sided P-value 
1.6 x 10-8) [WILLER et al., 2008]. 
 
LIPG 
Willer et al. reported an association between a variant within the lipase, endothelial 
(LIPG) gene and HDL-C. Rs2156552 was associated by a two-sided P-value of 6.4 x 
10-12 in the combined stage 1 and stage 2 analysis. Allele C at rs2156552 increased 
HDL-C concentration by 3.62 mg/dl [WILLER et al., 2008]. 
 
LPL 
Kooner et al. found five SNPs (rs325, rs326, rs328, rs174109, rs4406409) around the 
lipoprotein lipase (LPL) gene to be related to TG-levels. All SNPs, except for 
rs4406409, reached the genome-wide significance. To mention is that SNP rs326 was 
also significantly associated with HDL-C [KOONER et al., 2008]. 
The above-mentioned SNP rs328 was also found to be associated with HDL-C (P = 9 x 
10-23) and TG-level (P = 2 x 10-28) when carrying out a meta-analysis of one GWA and 
three replication studies [KATHIRESAN et al., 2008]. 
Another SNP, namely rs17482753, was shown to be associated with HDL-C (P = 3.6 x 
10-5) and TG (P = 4.9 x 10-7) by Saxena et al. [SAXENA et al., 2007]. 
Willer et al. showed that two variants (rs10503669, rs2197089) are associated with 
HDL-C and TG (for HDL-C: two-sided P-value of 4.1 x 10-19 and of 1.0 x 10-11; for TG 
two-sided P-value of 3.9 x 10-22 and of 1.1 x 10-12, respectively) in the combined stage 1 
and stage 2 analysis. Moreover, they showed SNP rs6586891 to be associated with 
HDL-C (two-sided P-value of 2.9 x 10-9) [WILLER et al., 2008]. 
 
PCSK9 
Kathiresan et al. confirmed that variants within the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) gene influence LDL-C concentration when analysing 
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pooled data form the DGI GWAS and three replication studies. Variant rs11591147 was 
significantly associated with LDL-C (P = 2 x 10-44) [KATHIRESAN et al. 2008]. 
Willer et al. also showed association between a variant within PCSK9 and LDL-C. 
Rs11206510 was associated by a two-sided P-value of 3.5 x 10-11 in the combined stage 
1 and stage 2 analysis. Allele T increased LDL-C concentration by 3.04 mg/dl 
[WILLER et al., 2008]. 
 
Newly associated genes 
In February 2008, three GWASs were published that investigated whether common 
variants are associated with HDL-C, LDL-C and TG [KOONER et al., 2008; 
KATHIRESAN et al, 2008; WILLER et al., 2008]. All in all, they identified eight 
newly associated loci (MLXIPL, ANGPTL3, MVK and MMAB, GALNT2, CELSR2-
PSRC1-MYBPHL-SORT1, TRIB1, NCAN, PBX4 and CILP2) and more than a dozen 
previously implicated genes were confirmed (Figure 13) [LUSIS and PAJUKANTA, 
2008]. The newly found association of GCKR and TG-level was already reported in 
2007 [SAXENA et al., 2007]. This finding increased the number of newly associated 
genes respectively gene regions to nine (Table 12). 
 
Table 12. Nine newly associated gene regions implicated in lipid concentrations 
Newly associated gene regions implicated in lipid concentrations identified by GWASs 
[KOONER et al., 2008; KATHIRESAN et al, 2008; WILLER et al., 2008; SAXENA et 
al. 2007] and associated traits 
Closest gene(s) Associated trait 
 LDL-C HDL-C TG 
ANGPTL3   x  
CELSR2-PSRC1-
MYBPHL-SORT1 
x   
GALNT2  x  
GCKR   x 
MLXIPL  x x 
MVK and MMAB  x  
NCAN x   
PBX4 and CILP2 x   
TRIB1   x 
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Figure 13. Primary pathways for the metabolism of human plasma lipoproteins  
The intestine secrets triglyceride (TG)-rich lipoproteins as chylomicrons and the liver as 
VLDL. Lipolysis in the circulation subsequently delivers fatty acids to tissues. 
Chylomicron remnants and about half of the VLDL remnants are taken up by the liver, 
while the remainder of the VLDL remnants is further metabolised to cholesterol-rich 
LDL, the main cholesterol carrying particles in humans. Lipid-poor apolipoproteins 
secreted by liver and intestine and surface components sloughed during lipolysis of TG-
rich lipoproteins lead to the formation of HDL in circulation. Blue symbols indicate 
previously identified genes confirmed in these studies to contribute to common 
variations in the concentrations of the major lipoproteins. Loci or genes newly identified 
in these genome-wide association studies are shown in red. 
 
[LUSIS and PAJUKANTA, 2008] reproduced 
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GCKR 
In the GWAS of the Diabetes Genetics Initiative (DGI) of Broad Institute of Harvard 
and MIT and Novartis Institutes for BioMedical Research it was reported that the SNP 
rs780094 within the glucokinase regulatory protein (GCKR) gene is associated with 
triglyceride levels (P = 3.7 x 10-8). That variation was responsible for 1% of the residual 
variance in TG levels. This association was confirmed by testing another 5,217 
individuals from the Malmö Diet and Cancer Study, Cardiovascular Arm (P = 8.7 x 10-
8) [SAXENA et al., 2007].  
Willer et al. replicated the association between the variant rs780094 and TG (two-sided 
P-value of 6.1 x 10-32) in the combined stage 1 and 2 two analysis. Allele T at rs780094 
increased TG concentration by 8.59 mg/dl [WILLER et al., 2008]. 
GCKR encodes for a protein that inhibits the pancreatic and hepatic glucokinase [Ridker 
et al., 2008]. Glucokinase is the first glycolytic enzyme and overexpression of 
glucokinase has been shown to lower fasting blood glucose and increase triglyceride 
levels [SAXENA et al., 2007]. 
 
MLXIPL 
Kooner et al. showed a significant association of TG and HDL-C with the 
nonsynonymous SNP rs3812316 (G771C, Gln241His) within the MLX interacting 
protein-like (MLXIPL) gene in the combined analysis of stage 2 and stage 3 data (P = 
9.9 x 10-8). The nonsynonymous SNP conferred an odds ratio of 1.29 per copy of the 
major C allele for TG levels > 1.7 mmol/l [KOONER et al., 2008]. 
In the GWAS conducted by Kathiresan et al., SNP rs17145738 within MLXIPL was 
associated with blood TG (P = 7 x 10-22) [KATHIRESAN et al., 2008].  
Willer et al. found the same SNP (rs17145732) as Kathiresan et al. to be associated with 
TG. Allele C increased TG concentration by 8.21 mg/dl [WILLER et al., 2008]. 
The product of the gene MLXIPL is involved in the glucose and triglyceride 
metabolism as well as in the regulation of the energy storage [LUSIS and 
PAJUKANTA, 2008]. 
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Additional susceptibility genes 
Despite no association with blood lipids was found by the reviewed GWASs, the 
following genes are worth to mention in this chapter. Both are discussed as MetSyn 
candidate genes [SONG et al., 2006] and were found by GWAS that investigated other 
MetSyn traits [SCOTT et al., 2007; FOX et al., 2007]. 
 
Table 13. 2 additional susceptibility genes associated with lipid concentrations 
Genes associated with lipid concentrations identified by GWASs that investigated 
T2DM [SCOTT et al., 2007] or obesity related features [FOX et al., 2007] 
Closest gene Associated trait 
 LDL-C HDL-C TG 
PPARG x   
ADIPOQ x   
 
 
PPARG  
The Ala12 variant (rs1801282) within PPARG was associated with T2DM in a 
protective manner [SCOTT et al., 2007]; however, that SNP is suggested to be 
associated with blood lipid levels too. This was recently confirmed in a study conducted 
in 285 obese children and adolescents. The SNP was not associated with BMI, HDL-C, 
TG or IR, but wild type carriers of PPARG Pro12Ala (P < 0.05) had higher total and 
LDL-C levels adjusted for age, gender, BMI and insulin sensitivity [JOHANSSON et 
al., 2008]. 
 
ADIPOQ  
The candidate gene study conducted by Johansson et al. genotyped also the G276T SNP 
within ADIPOQ. They found that homozygous (TT) carriers of the G276T have higher 
total and LDL-C levels adjusted for age, gender, BMI, and insulin sensitivity (P < 
0.001). Like the PPARG variation, the ADIPOQ variation was not associated with BMI, 
HDL-C, TG, or IR. Interestingly, they calculated a combined risk resulting from a 
PPARG Pro/Pro and an ADIPOQ 276 T/T genotype. The carriers of that genotype had 
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higher total (5.0; CI 4.1-5.8 vs. 4.1; CI 3.6-4.6 mmol/l) and LDL-C levels (3.7; CI 95% 
2.9-4.5 vs. 3.0; CI 95% 2.5-3.5 mmol/l) compared with carriers of other combinations 
(P < 0.001) [JOHANSSON et al., 2008]. 
The hormone adiponectin is implicated in the regulation of the lipid metabolism, the 
glucose metabolism, and the energy homeostasis. It is secreted by adipocytes [SONG et 
al. 2006]. 
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2.7.4 Hypertension 
The aforementioned Wellcome Trust Case Control Consortium (WTCCC) investigated 
the association of SNPs with T2DM in a GWAS of 14,000 cases and 3,000 shared 
controls, but they also investigated six other common diseases. One of those diseases 
was hypertension. However, they only found moderate evidence for association (range 
of the P-value: 10-4 to 10-7). Misclassification bias due to the presence of hypertensive 
individuals within the control samples was seen as one explanation for that findings 
[THE WELLCOME TRUST CASE CONTROL CONSORTIUM, 2007].  
Another GWAS that aimed to investigate blood pressure and arterial stiffness 
(Framingham Heart Study 100 K Project; included up to 1,327 individuals) neither 
found associations that reached genome-wide significance. The best association was 
seen between diastolic blood pressure and the intergenic variant rs1963982 (P = 3.31 x 
10-6) and between systolic blood pressure and the intergenic rs10493340 (P = 1.7 x 10-
6). The authors call for further GWASs with larger sample sizes and more dense 
genome-wide coverage of common variants [LEVY et al., 2007]. 
 
 
Additional susceptibility genes 
PPARG 
PPARG is a discussed MetSyn candidate gene [SONG et al., 2006], in spite of that no 
association with blood pressure or blood lipids was found by the reviewed GWASs for 
that gene and only a not genome-wide significant association was reported for T2DM 
[SCOTT et al., 2007]. However, it is worth to mention in this part, as candidate gene 
studies also support a role of that gene in hypertension. 
The Ala allele of the variant Pro12Ala (rs1801282) within the PPARG gene has been 
associated with protection against T2DM [SCOTT et al., 2007]. In contrast, a 
population-based study of 934 high-school students of Caucasian origin showed that 
carriers of the 12Ala variant have higher diastolic blood pressure (P = 0.002) and lower 
puls pressure than non-carriers, particularly in hypertensive and overweight adolescents 
with features of the MetSyn [SOOKOIAN et al., 2005]. 
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2.7.5 Inflammation – CRP 
Although the assessment of the C-reactive protein (CRP) level is not required to 
diagnose somebody with the MetSyn, evidence exists that elevated levels of CRP 
independently predict incident MetSyn, T2DM, myocardial infarction and stroke in 
healthy men and women. Because of the seen importance of that protein and the known 
heritability, a GWAS aimed to investigate the influence of the genetic variation on CRP 
level. This was done among 6,345 apparently healthy women in the Women’s Genome 
Health Study. They identified seven loci (46 SNPs) to be in an association with plasma 
CRP at levels achieving genome-wide statistical significance (P = from 1.9 x 10-8 to 6.2 
x 10-28 for lead SNPs within the seven loci). Those common variants explained 10.1% 
of the remaining variation in CRP after adjustment for the clinical and environmental 
factors (Table 14). The polymorphism in the CRP gene explained the most remaining 
variation (3.4%) compared to the others [RIDKER et al. 2008]. 
 
Table 14. Seven gene regions associated with plasma CRP levels 
Women’s Genome Health Study data 
 
Number of SNPs 
clustered in 
chromosome locus 
Closest gene Chromosome 
locus 
Locus-wide 
variance 
explained (%) 
2* APOE 19q13.32 1.5 
20* CRP 1q23.2 3.4 
3* GCKR 12q23.31 1.1 
8* HNF1A 12q24.31 1.1 
2 IL6R 1q21.3 0.6 
9* LEPR 1q31.3 1.6 
2 Unknown 12q23.2 0.8 
*Remained significant after the analyses was restricted to those study participants 
with CRP levels < 10 mg/l; Results were adjustment for age, smoking, BMI, 
hormone therapy, and menopausal status 
[RIDKER et al., 2008] modified 
 
  
67 
2.7.6 Metabolic syndrome itself 
Each MetSyn component, except hypertension, was previously associated genome wide 
significantly with gene variants; nevertheless, it is currently unknown if the interaction 
of such variants leads to the development of the MetSyn or if there is a MetSyn locus, 
which is alone responsible for the onset of the disease. Latter theory was and is 
investigated by linkage studies. 
 
 
Linkage studies 
In 2006, a genome-wide linkage scan using 250 German families (affected sib pairs 
only) was published that supported the existence of a MetSyn locus on chromosome 
1p36.13 (37.05cM, D1S3669). The scan aimed originally to identify T2DM risk loci 
only, but when the researchers compared their results with results from former linkage 
scans, evidence for a MetSyn locus appeared; other studies had already reported 
linkages with parameters of lipid metabolism, hypertension and obesity close to their 
identified T2DM locus [HOFFMANN et al., 2007]. Interestingly, that linkage study 
reported no linkage to the previously mentioned region around DG10D478, which was 
found to be associated with T2DM in Icelandic, Danish, and US cohorts [GRANT et al. 
2006].  
Another linkage analysis (n = 4,549) showed that the composite factor (BMI, WHR, 
subscapular skinfold, TG, HDL-C, HOMA, plasminogen activator inhibitor-1 antigen, 
and serum uric acid) is significantly associated (LOD 3.34) with a region between 
D2S427 and DS21279 on chromosome 2q36. Chromosomes 7, 12, 14, and 15 showed 
suggestive associations (LOD between 2.42 and 2.84) [TANG et al., 2003].  
Edwards et al. recently confirmed a linkage for MetSyn phenotypes on chromosome 2, 
but at a different position (2q12.1-2q13) [EDWARDS et al., 2008]. 
Obviously, various chromosomal regions have emerged that are linked to the MetSyn 
and even more chromosomal regions spanning several thousand genes are linked to 
MetSyn components. In a recently published review a clue was given, how many 
chromosomal regions or how many genes are suggested to be associated. The 
researchers used a bioinformatics tool (ENDEAVOUR) to prioritise the selection of 
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candidate genes in MetSyn and listed the first 20 genes out of 1,518 (located in 
chromosomal regions previously associated with MetSyn components). CYP3A43 
(7q21.1), INSRR (1q21-q23), ADIPOQ (3q27), and SERPINC1 (4q21) are several of 
the first listed genes [SOOKOIAN and PIROLA, 2007].  
 
Candidate gene studies 
As already mentioned, no GWAS was published so far – to my knowledge – that 
directly investigated the association of gene variants with the MetSyn. For that reason, 
some results from candidate gene studies are presented that showed direct gene 
associations with the MetSyn. Only genes with former evidence from GWASs are 
discussed. 
 
Table 15. Five genes associated with MetSyn components and with the MetSyn 
itself  
Genes associated with MetSyn components identified by GWASs [RIDKER et al., 
2008; CHAMBERS et al., 2008; SCOTT et al., 2007] and with the MetSyn itself as 
identified by candidate gene studies [SIMA et al., 2007; HEID et al., 2008; AL-ATTAR 
et al., 2008] 
Closest 
gene 
Associations 
 T2DM, 
HOMA-IR% 
obesity blood 
lipids 
hypertension CRP 
APOA5   x   
APOE     x 
FTO x x    
MC4R x x    
TCF7L2 x     
 
 
APOA5 
A recently published candidate gene study showed that the coding SNP rs3135506 
(c.56C > G) within APOA5 is directly associated with the MetSyn. The study was 
conducted in 1,354 Caucasian subjects of the population-based Cooperative Health 
Research in the Region of Augsburg (KORA) survey S4 and in 1,770 subjects of the 
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Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk 
(SAPHIR) Study. The association between APOA5 and MetSyn itself as well as the 
association with features of the MetSyn (lipid parameters, WC, glucose-related 
parameters, blood pressure, uric acid) was investigated. It was reported that the minor 
allele of rs3135506 is significantly associated with higher TG levels and lower HDL-C; 
latter was only significant in the SAPHIR population. None of the other MetSyn related 
features was associated, nevertheless, MetSyn (as defined by NCEP-ATPIII criteria) 
was directly associated. In the additive model, SNP rs662799 increased the MetSyn risk 
in the KORA population 1.43-fold (95% CI 1.04-1.99; P = 0.03) and 1.48-fold in the 
SAPHIR population (95% CI 1.10-1,99; P = 0.009). Only the association in the 
SAPHIR population remained significant after correction for multiple testing. The 
authors reported, furthermore, that an additional SNP (rs662799, 1131T>C) might have 
an additive effect to the effect seen with rs3135506. The estimated MetSyn risk was 
increased (but not significantly) in subjects heterozygous for minor alleles of both 
variants [GRALLERT et al., 2007]. 
 
APOE 
This gene was directly associated with the MetSyn in a small candidate gene study (n = 
279). The subjects were divided into a control group (1), a MetSyn group (2) and a 
group of obese patients with coronary heart diseases (3). They found a higher frequency 
of the apo E4/3 genotype in the second and the third group as well as higher levels of 
TG and lower levels of HDL-C compared to group 1. Sima et al. concluded, therefore, 
that the epsilon 4 allele is an independent risk factor for MetSyn [SIMA et al., 2007]. 
 
FTO 
FTO was associated with the MetSyn directly in a candidate gene study conducted in a 
non-Caucasian multi-ethnic sample (n = 2,121; Canadians of South Asian and Chinese 
descent, Oji-Cree, Inuit). The researchers reported an increased risk of MetSyn when 
carrying an rs9939609 A allele (Table 16). This was especially true for men. Individuals 
with ≥ 1 copy of the rs9939609 A allele were significantly more likely to have IDF-
defined MetSyn (35.8%) than those individuals carrying no copy (31.2%). The results 
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for NCEP-ATP III-defined MetSyn were very similar to the results for IDF-defined 
MetSyn. This association was induced by a higher proportion of subjects with lowered 
HDL-C and a trend towards increased WC [AL-ATTAR et al., 2008]. Although this 
study was conducted in non-Caucasians, it might be that the variant shows a similar 
association in Caucasians, because SNP rs9939609 was repeatedly associated with 
increased BMI and T2DM in Caucasians [THE WELLCOME TRUST CASE 
CONTROL CONSORTIUM, 2007; FRAYLING et al., 2007a].  
 
Table 16. MetSyn prevalence in subjects when classified in accordance to their 
FTO genotype  
Data is shown for SNP rs9939609  
 TT carriers 
in % 
AA&AT 
carriers in % 
OR 95% CI P-value 
IDF  31.2  35.8 1.12 (1.01-1.50) 0.036 
NCEP-ATPIII 21.1 25.2 1.26 (1.02-1.57) 0.036 
[AL-ATTAR et al., 2008] modified 
 
MC4R 
That MC4R SNP V103I (rs2229616) is associated with features of the MetSyn was 
shown in a population-based cross-sectional study (n = 7,888), with allele 103I to be 
protective. Furthermore, those individuals carrying a 103I polymorphism had a reduced 
risk of having three or more components of the MetSyn (OR 0.43, P = 0.003). The exact 
implication mechanism is not known yet, but it is thought that the variant influences 
appetite regulation, physical activity, and dietary intake. Results from that study support 
that theory, because MC4R102I showed a borderline association with carbohydrate 
intake (OR = 1.26, P = 0.059) [HEID et al., 2008]. 
SNP V103I is not the only variation within MC4R that is associated with the MetSyn. 
Variants (rs12970136, rs477181, rs502933, rs4450508) were also shown to be 
associated with the MetSyn and with features of the MetSyn (Table 9). For example, 
SNP rs12970134 increased the risk of MetSyn 1.12-fold (95% CI 1.06-1.20; P = 2.3 x 
10-4) in all stage 2 participants (n = 11,955). To note is that stage 2 included a 
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population of Indian Asian ancestry and a population of European ancestry 
[CHAMBERS et al., 2008]. 
 
TCF7L2 
Two candidate gene studies published opposite findings regarding the association of 
TCF7L2 variants with the MetSyn.  
Marzi et al. confirmed that rs12255372 and rs7903146, both within the TCF7L2 gene, 
are strongly associated with T2DM, but they also showed in that population-based study 
comprising 1,404 male and female KORA participants aged 55-74 years that those 
SNPs are not related to the MetSyn as defined by the IDF or by NCEP [MARZI et al., 
2007]. 
Sarzani et al. studied 204 obese and hypertensive patients (<65 years old) without 
T2DM and 222 unselected adults. They found that obese and hypertensive patients with 
the MetSyn (defined by NCEP-ATPIII criteria) have higher frequencies of TCF7L2 
DG10S478 allele X (66.2%) than those without MetSyn (40%). Individuals with 
DG10S478X had a 2.94-increased risk (95% CI 1.37-6.28, P = 0.0006) to develop the 
MetSyn in an unadjusted model. The effect size was even higher when they adjusted for 
age, gender, BMI, and rs7903146 (OR 3.25; 95% CI 1.43-7.4; P = 0.005) [SARZANI et 
al., 2008].  
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3 Discussion 
The number of different MetSyn-definitions makes a statement about the quality of each 
definition to a rather daunting task. The most important definitions (in numbers 6) are 
described in that paper. A number of six definitions does not sound that much and those 
definitions seem – at the first glance – not too different, but on closer examination, one 
can see momentous differences [DAY, 2007]. This was pointed out by showing 
different prevalence rates. For example, the assessed MetSyn prevalence in men ranged 
from 27% to 35.9% according to definitions of WHO, NCEP-ATPIII and IDF [THE 
DECODE STUDY GROUP, 2005]. To determine the quality of a definition or to give a 
recommendation, which definition to prefer with regard to the prediction of CVD and 
T2DM – one has to investigate studies that compared different definitions in the same 
population and under the same conditions at best. There are indeed some studies, even 
meta-analyses, that compared the definitions and those also came up with some 
suggestions; nonetheless, the results are to question, because they did not compare all 
definitions among each other and meta-analyses only exists, to my knowledge, for the 
prediction of CVD.  
 
What can be stated is that every definition has its advantages and disadvantages. To 
illustrate the point, the WHO definition is due to the presence of IR more difficult to 
implement in clinical practice. In addition, the criteria are often modified when used in 
studies, because microalbuminuria data is lacking, and finally, a rather low sensitivity to 
identify persons at risk on MetSyn was attributed to that definition [LORENZO et al., 
2007]. Nonetheless, the WHO definition seems to be on forefront to predict CVD 
[GAMI et al., 2007] and T2DM [LORENZO et al., 2007] when comparing the RRs (or 
ORs). In that context it is to mention that individuals with the MetSyn have a ~ 2-fold 
increased risk for CVD and a ~ 6-fold increased risk for T2DM [LORENZO et al., 
2007]. That sounds a lot, but this does not imply a practical effect, because the MetSyn 
was shown to be inferior to the established disease predicting models (Diabetes Risk 
Score, Framingham Risk Score) [GRUNDY et al.; 2005; STERN et al.; 2004, 
LORENZO et al. 2007]. Even an addition to the risk, assessed by the Diabetes Risk 
Score and the Framingham Risk Score is unclear [STERN et al., 2004]; if it adds, the 
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question arises whether the MetSyn adds to the risk as a syndrome or whether the 
simple summation of the risks conferred by the single components is pivotal [GAMI et 
al., 2007; THE DECODE STUDY GROUP, 2006; LAWLOR et al., 2006]. Further 
investigations are needed to clear the essential question whether the MetSyn is more 
than the sum of its components.  
 
In face of a questioned existence of the MetSyn and inferiority to the established 
predicting models, there are still some positive aspects about the MetSyn.  
First, it is assumed that the MetSyn is useful to assess people who are on long-term risk 
(> 10 years) for CVD; whereas Framingham Risk Score should be performed to 
estimate 10-year risk [GRUNDY et al. 2005]. Second, it was shown that the MetSyn 
may complement Framingham scoring for men aged ≥ 45 years and women aged ≥ 55 
years and that the prediction of T2DM is beyond glucose intolerance alone [LORENZO 
et al., 2007]. Third, the DECODE Study Group justified the use of the MetSyn in 
clinical practice, because the MetSyn detect further men at risk of cardiovascular death 
beyond those identified by a risk score [THE DECODE STUDY GROUP, 2007] and 
finally the syndrome can serve as a reminder in clinical practise. Physicians might be 
encouraged to search for additional metabolic abnormalities when one component of the 
MetSyn occurs.  
In spite of all the disadvantages shown in this paper, the positive aspects of the MetSyn 
overweigh to my opinion. The evidence leads to the assumption that the MetSyn is at 
least useful to identify additional individuals at long-term risk, which could benefit from 
early prevention measures like lifestyle modifications (weight loss, increased physical 
activity, healthy diet) [LEVESQUE and LAMARCHE 2008]. With the population 
getting older, it is especially important to fight against an increasing prevalence, as the 
MetSyn is age-dependent [FORD et al., 2008]. The older the individuals, the higher the 
MetSyn prevalence, and the more individuals would benefit from an early prevention. 
 
To assess individuals who are at-risk to develop the MetSyn and subsequently CVD and 
T2DM, one has to consider that the interplay of environmental factors and genetic 
variations is thought to be causative for the MetSyn [SONG et al., 2006].  
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A genetic contribution to the development of the MetSyn is not to deny, because the 
MetSyn and its components are heritable, with components having a higher heritability 
and with components having a lower heritability. An example for latter one is systolic 
blood pressure, with heritability estimates between 14% [FREEMAN et al. 2002] and 
28% [MILLS et al., 2004], but also the heritability for the MetSyn itself is not so high. 
The highest estimate was 24% [LIN et al., 2005], but that study was conducted in a 
Caribbean Hispanic high-risk population leading to the assumption that the heritability 
in a European not at-risk population might be lower. The heritability for HDL-C is, 
however, rather high. The estimates range from 44% [FREEMAN et al., 2002] to 76% 
[SOUREN et al., 2007]. The range of variety may surprise, but can be partly explained 
by the heterogeneity of the studies (different study population with different genetic 
background, different statistical methodologies).  
 
As the evidence for the genetic contribution to the development of the MetSyn is 
conclusive it makes subsequently sense to search for susceptibility genes, but that is less 
easy than one had expected. As discussed above, there are a number of MetSyn 
definitions; that is a problem for the search of susceptibility genes, because studies 
apply different definitions, thus the results are hardly to compare. However, this is not 
the only problem. None of those definitions is precise and that hinders the identification 
of genes involved in the disease on a basic principle. How can a genotype be related to a 
not defined phenotype? It is remarkable how many phenotypes are feasible, when 
somebody is diagnosed with the MetSyn [DESPRÉS and PÉRUSSE, 2008]. This 
phenotype variety occurs due to the reason that the discussed definitions require either 
obesity or IR or no special criteria for their definition and not all of the additional 
components have to be fulfilled. An example: A person with an elevated waist 
circumference, hypertension and reduced HDL-C and a lean person with elevated TG, 
elevated fasting glucose and hypertension are both diagnosed with the MetSyn by the 
AHA/NHLBI definition. In consequence of this phenotype variety, a precise definition 
has to be created, before any approach of finding susceptibility genes is applied. 
Anyhow, several genes were identified by GWASs to be associated with MetSyn 
components or with CRP, which elevated levels are assumed to independently predict 
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incident MetSyn [RIDKER et al. 2008]. Some of those genes were linked to the MetSyn 
itself or/and with MetSyn components in candidate gene studies too (Table 17).  
 
Table 17. Ten gene regions implicated in MetSyn components identified by 
GWASs and partly linked to MetSyn in CGSs 
Gene or 
gene cluster 
Associations 
 T2DM, 
HOMA-
IR%, FPG 
obesity dys-
lipidemia 
hyper-
tesion 
CRP MetSyn 
ADIPOQ  GWAS$ CGS    
APOA1-
APOC3-
APOA4-
APOA5 
  GWAS   CGS 
APOE   GWAS  GWAS CGS 
CETP   GWAS#    
FTO GWAS GWAS    CGS* 
GCKR GWAS  GWAS  GWAS  
IL6R  GWAS$   GWAS  
LEPR  GWAS$   GWAS  
MC4R GWAS GWAS    CGS 
PPARG GWAS$ GWAS$ CGS CGS   
TCF7L2 GWAS     CGS 
* Not in Caucasians; # Stage 1 conduced in a MetSyn population; GWAS gene wide 
association study; CGS candidate gene study; $ not genome-wide significant 
 
 
As one can notice, no GWAS was published so far that investigated the MetSyn itself. 
Anyhow, it is currently unknown if there is a MetSyn locus, which is alone responsible 
for the onset of the disease or if the interaction of polymorphisms located within or near 
the genes associated with the MetSyn components leads to the development of the 
MetSyn. Assuming the latter theory, several disease susceptibility genes with more or 
less evidence exist. Each of them will be discussed briefly to summarize the evidence. 
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ADIPOQ 
Song et al. stated in their review that “biochemical, cellular, animal, and human 
epidemiological data support the role of adiponectin in MetSyn” [SONG et al., 2006]. 
This assumed implication of ADIPOQ variations in the development of the MetSyn is 
underpinned by another review [SOOKOIAN and PIROLA, 2007]. Moreover, a SNP 
within ADIPOQ (G276T) was associated with higher total and higher LDL-C in a small 
candidate gene study [JOHANSSON et al., 2008]. Anyhow, ADIPOQ was only found 
in one GWAS to be associated with obesity and that finding did not reach genome-wide 
significance [FOX et al. 2007].  
 
APOA1-APOC3-APOA4-APOA5 
GWASs showed that SNPs near or within the APOA1-APOC3-ACOA4-APOA5 cluster 
are strongly associated with the TG-level and account for effect sizes up to 25.82 mg/dl 
[WILLER et al., 2008]. Noteworthy, one of these GWASs carried out their initial 
genome scan in individuals affected by the MetSyn [KOONER et al., 2008]. An 
association with HDL-C was also shown by one GWAS, but that association was not 
genome-wide significant [KATHIRESAN et al., 2008]. Additionally to the found blood 
lipid associations, it was shown by a candidate gene study that the variant rs3135506 
within APOA5 increases the risk of MetSyn in the range from 1.43-1.48. Moreover, 
evidence exists that the variant rs662799 within the cluster also increases the risk of 
MetSyn [GRALLERT et al., 2007]. Most interestingly, this variant belongs to the 
before mentioned SNPs that are associated with the TG-level [WILLER et al., 2008].  
 
APOE cluster 
The APOE polymorphisms C112R (rs429358) and R158C (rs7412), responsible for the 
APOE isoforms, are known to influence the lipid levels of children and adults. 
[JOHANSSON et al., 2008]. Both were directly associated with the MetSyn by a 
candidate gene study [SIMA et al., 2007]. However, those SNPs were not identified by 
GWASs. Instead of, SNP rs4420638 showed overwhelming evidence (P = 1 x 10-60) for 
the association with LDL-C [KATHIRESAN et al., 2008]. In addition, SNPs rs769449 
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and rs2075650 were identified to be associated with CRP-levels with genome-wide 
significance [RIDKER et al., 2008]. 
 
CETP 
Although this gene was only associated with HDL-C and apoA-I in GWASs 
[KATHIRESAN et al., 2008; SAXENA et al., 2007; KOONER et al., 2008], a further 
investigation would be interesting. This is motivated by the fact that one of the GWASs 
carried out their initial genome wide scan in European men affected by the MetSyn and 
in that initial scan, SNP rs711752 within CETP was significantly associated with HDL-
C [KOONER et al., 2008]. 
 
FTO 
Hinney et al. reviewed the latest findings regarding gene-obesity associations. They 
stated that the variants within FTO belong to those gene variants that are truly 
associated with obesity [HINNEY and HEBEBRAND, 2008]. The findings of this 
thesis confirm this statement. GWASs showed that FTO-variants are involved in the 
development of T2DM via modulation of BMI [SCOTT et al., 2007]. Furthermore, 
FTO-variants modulate weight, WHR, WC, and FM [DO et al., 2008]. Risk of 
overweight and obesity are also influenced by those polymorphisms. Although each 
additional risk allele copy of the most promising SNP (rs9939609) increase BMI of a 
mean of 0.10 Z-score units (95% CI 0.08-0.12; P = 2 x 10-20, equivalent to ~ 0.4 kg/m-2) 
it accounts only for 1% of BMI variance [FRAYLING et al., 2007a]. 
 
GCKR 
Variant rs780094 showed associations with the TG-level in GWASs [SAXENA et al., 
2007; WILLER et al., 2008] and was associated by a P-value of 6.73 x 10-15 with CRP-
levels [RIDKER et al. 2008], whereas another SNP (rs1260326) within GCKR showed 
an additive effect on FPG [BOUATIA-NAJI et al., 2008]. Noteworthy, the evidence 
that GCKR influence TG-levels was newly ascertained by GWASs. Considering all 
evidence, this gene becomes a new interesting candidate gene. 
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IL6R 
This gene was related to mean WC in a GWAS, but not with a genome-wide 
significance [FOX et al., 2007]. Interestingly, the same SNP that was associated with 
mean WC was also associated with plasma CRP levels and this time the association 
reached genome-wide significance. SNP rs4129267 was related to CRP level with a P-
value of 1.97 x 10-8 [RIDKER et al., 2008]. 
 
LEPR 
This gene is an attractive candidate gene, because of its known function. Despite of that, 
it was only identified by one GWAS as obesity associated gene and not even with 
genome-wide significance [FOX et al., 2007]. However, a GWAS found nine SNPs 
within that gene to be associated with plasma CRP levels (P < 3.28 x 10-9) [RIDKER et 
al., 2008].  
 
MC4R 
Variants of MC4R have been associated with BMI, weight, height, fat mass, risk of 
overweight/obesity [LOOS et al., 2008], and waist circumference [CHAMBERS et al., 
2008]. The previously by candidate gene studies identified association between SNP 
Val103Ile and BMI (effect size of the 103Ile allele -0.5 kg/m-2) [HINNEY and 
HEBEBRAND, 2008] was not identified by the reviewed GWASs. Instead of, SNP 
rs17782313 within MC4R showed the best evidence. That SNP showed a per-allele 
effect of 0.049 (95% CI 0.037-0.061 Z-score units; equivalent to 0.22 kg m-2) with a P-
value of 2.8 x 10-15 in adults. Although common variants near MC4R influence obesity 
traits, they make only a modest contribution to overall variance (~0.14 % for adult BMI) 
[LOOS et al., 2008]. Furthermore, variants of that gene have been associated with 
HOMA-IR in one GWAS, which was conducted in a population of Indian Asian 
ancestry [CHAMBERS et al. 2008]. To what extent an association with HOMA-IR in a 
population of European ancestry exist, remain to be investigated.  
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PPARG 
PPARG is assumed to be a MetSyn candidate gene [SONG et al., 2006], however, the 
evidence therefore is not convincing. Even if a meta-analysis of three GWASs and one 
separate GWAS found associations between variant rs1801282 (Pro12Ala) within 
PPARG and T2DM that are close to genome-wide significance [SCOTT et al., 2007; 
ZEGGINI et al., 2008], inconclusive results were shown by a meta-analysis of 43 CGS 
[LUDOVICO et al., 2007]. In addition, a GWAS found no association of SNP 
rs1801282 with mean BMI or mean WC, but six other SNPs within PPARG were 
related to; notably the prespecified genome-wide significance level was not reached 
[FOX et al., 2007]. Moreover, associations with LDL-level [JOHANSSON et al., 2008] 
and hypertension [SOOKOIAN et al., 2005] were shown by candidate gene studies. 
 
TCF7L2  
The association between SNPs within TCF7L2 and T2DM was first detected by linkage 
studies [GRANT et al., 2006] followed by candidate gene studies [WANG et al., 2007; 
ZHANG et al., 2006] and then confirmed by GWASs. Those GWASs showed that 
SNPs within that gene have good, if not the best associations in comparison to the other 
T2DM susceptibility genes [STEINTHORSDOTTIR et al, 2007; SCOTT et al., 2007]. 
Hence, variations within TCF7L2 are currently the most important ones that are 
associated with T2DM risk. The variant with the best evidence (rs7901695; P = 1 x 10-
48) leads, by risk allele, to a 1.37-fold increased T2DM risk [FRAYLING, 2007b]. 
Although there truly is an association with T2DM the association with MetSyn is to 
question. Two CGSs have published conflicting results, with variants (DG10S478X) to 
be associated [SARZANI et al., 2008] and variants (rs12255372, rs7903146) to be not 
associated [MARZI et al., 2007]. 
 
In my opinion, all of those genes qualify for a follow-up, but no recommendation can be 
given which SNP or SNPs within those genes should be investigated further. Anyhow, 
conspicuous is that those SNPs found formally in candidate gene studies to be 
associated, mostly were not identified by GWASs and when they were identified, the 
evidence was not with genome-wide significant. That leads to the assumption that we 
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were possibly stiffed on the wrong SNPs till now. It follows that we should focus more 
on the newly identified SNPs. 
 
A numerousness of gene variants has been identified, but as they all account for only 
modest effect sizes, they cannot be the answer to the seen trait-variations. Not either 
combining the effect sizes fills the gap as shown by various studies.  
Loos et al. provided data about the combined effect of a variant within FTO and a 
variant within MC4R. The BMI difference between adults with no risk alleles at either 
locus and those homozygous at both was ~1.17 kg m-2 [LOOS et al., 2008].  
Saxena et al. reported that even though each of the identified T2DM SNPs (within 
CDKN2B, IGF2BP2, CDKAL1, HHEX, SLC30A8, TCF7L2, KCNJ11, PPARG) 
account for a substantial population attributable risk, each contributes only little to the 
variation of diabetes risk (0.04 to 0.5%, ~2.3% combined across the eight SNPs) 
[SAXENA et al., 2007]. 
In the review of Lusis and Pajukanta it is stated that “despite the number of found 
associations, the SNPs that meet the genome-wide level of significance, including the 
previously identified genes, explain only 5-8% of the variation in HDL-C, LDL-C and 
TG, after accounting for sex, age and diabetes status“ [LUSIS and PAJUKANTA, 
2008]. 
In hypertension, however, GWASs have not provided any gene wide significant data so 
far [LEVY et al., 2007] and therefore no data for combined effect sizes is available. 
To what extent the hitherto identified genes, which are not included in those 
calculations, account for the variance is to question. Especially the contribution of 
CTNNBL1 to obesity and the contribution of the newly associated six T2DM gene 
regions is interesting, although those gene regions showed only modest ORs (1.09 to 
1.15) [SAXENA et al., 2007]. On the contrary, CTNNBL increased the odd ratios of 
obesity 1.42 fold and showed multiple BMI and fat mass effect sizes compared to FTO 
and MC4R, but only in one GWAS [LIU et al., 2008]. 
Obviously, many more loci remain to be found that account as risk factors for T2DM, 
obesity, hypertension, and dyslipidemia. Those could explain the remaining variance 
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seen in affected individuals. Alternatively, they have already found the right loci, but 
not the causative variants that explain bigger parts of the variance. Extensive 
resequencing and fine mapping is required to answer that question. Another possibility 
is, that variants with rarer frequencies (< 1%) compared to the so far investigated (> 
1%), but with bigger effect sizes, exist. 
Lots of speculations about the genetic contribution to the variance can be stated; 
however, one should not underestimate the chance that the remaining variance could 
arise from environmental factors too. Freeman et. al showed that unexplained trait 
variations ranged, still, from 32% to 59% after adjustment for genetic and household 
effects [FREEMAN et al., 2002]. In addition, it was shown that lifestyle-interventions 
reduce the risk conferred by genetic factors. That is because the association between the 
risk genotype and the risk of incident diabetes was only seen in the group without 
intervention [WANG et al., 2007]. 
 
As above pointed there are still several disease susceptibility genes and gene variants 
that have to be identified; but to identify is only one step. The further investigation, 
which should lead to the finding of causative variants and subsequently their pathways 
that contribute to pathogenesis, is crucial. To determine the pathways shows new 
opportunities to prevent and to treat a disease. Sladek et al. speculated for example that 
the knowledge of the association between the SNP within SLC30A8 and T2DM might 
lead to dietary interventions (zinc supplementation) or to the development of new 
medications [SLADEK et al, 2007]. 
 
In conclusion, well-designed GWASs offer great opportunities to identify genes and 
gene variants implicated in common diseases such as MetSyn. Anyhow, for a robust 
identification of variants with such small effect sizes as seen in common diseases large 
sample sizes or the exchange and pooling of data are needed, and with regard to the 
MetSyn – of course – a precise definition. 
One may be curious about the future GWASs findings. 
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4 Summary 
This thesis mainly intended to investigate the genetic determinants of the MetSyn and 
its components by reviewing gene-wide association studies (GWASs). Furthermore the 
most important definitions, the prevalence rates, the clinical relevance (a brief 
comparison of the MetSyn with established risk predicting models for CVD and T2DM 
is given), the underlying factors and the heritability estimates were discussed as well as 
the basic principles of a GWAS described.  
To determine which genes or gene variants are involved in the development of the 
MetSyn GWASs were reviewed that investigated gene associations with components of 
the MetSyn, C-reactive protein or with known outcomes, like T2DM. This approach 
was due to the reason that no GWAS was published so far that investigated the MetSyn 
directly and the assumption that the interaction of gene variants associated with MetSyn 
components leads to the development of the MetSyn. The results of the reviewed 
GWASs were then compared and the ten genes or gene regions with overlapping or 
particular evidence (genome scan was conducted in individuals affected by the MetSyn) 
were discussed briefly to summarize the evidence. 
The most important genes implicated in the development of the MetSyn seem to be 
APOE, FTO, GCKR, MC4R, and PPARG. SNPs of these genes are associated with at 
least two MetSyn components with genome-wide significance except of PPARG, which 
significance was borderline. Interestingly, those SNPs found formally in candidate gene 
studies to be associated, mostly were not identified by GWASs; for instance the variant 
of MC4R Val103Ile. All of the so far associated SNPs account only for modest effect 
sizes; therefore, they cannot explain the observed trait variations. Even the summation 
of effect sizes could not explain, for instance, more then 5-8% of the variation seen in 
blood lipids. It follows that many more implicated gene variants or other contributors to 
the observed trait variation, as environmental factors, have to be identified. 
In conclusion, genetic variations influence the development of MetSyn components and 
the MetSyn itself, but to what extent remains unanswered. However, the GWAS is a 
powerful method to further investigate the genetic contribution and the genetic 
determinants of the MetSyn and its components. 
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5 Zusammenfassung 
Das Ziel dieser Diplomarbeit war es, die genetischen Determinanten des MetSyn durch 
ein Literaturreview der betreffenden genomweiten Assoziationsstudien (GWASs) zu 
bestimmen. Weiters wurden die wichtigsten Definitionen des MetSyn, die 
Prävalenzraten, die klinische Relevanz (dazu wurde das MetSyn mit bestehenden 
Prognosemodellen für kardiovaskulare Erkrankungen oder Diabetes verglichen), die zu 
Grunde liegenden Faktoren und die Heretabilität diskutiert sowie die Grundlagen einer 
GWAS beschrieben.  
Zur Bestimmung der involvierten Gene bzw. Genvarianten wurden GWAS 
herangezogen, die Genassoziationen mit Komponenten des MetSyn sowie mit C-
reaktiven Protein und Folgeerkrankungen, wie z.B. Diabetes mellitus untersuchten. 
Dieser Ansatz begründet sich dadurch, dass noch keine GWAS publiziert wurde, die das 
MetSyn als solches untersucht hat sowie durch die Annahme, dass die Interaktion 
verschiedener Genvarianten assoziiert mit den Komponenten des MetSyn zur 
Entwicklung des MetSyn beitragen kann.  
Der Vergleich der durch die GWASs als assoziiert identifizierten Gene zeigte, dass 
neun Gene sich auf verschiedene MetSyn Komponenten gleichzeitig auswirken. Ein 
zehntes Gen wird dadurch interessant, da dessen Identifikation anhand einer an MetSyn 
erkrankten Gruppe erfolgte. Die Evidenz aller zehn Gene wird zusammengefasst 
dargestellt und diskutiert. 
Zu den Genen mit der besten Evidenz zählen APOE, FTO, GCKR, MC4R und PPARG. 
Varianten dieser Gene wurden mindestes mit zwei Komponenten des MetSyn assoziiert, 
mit einer den genomweiten Assoziationsstudien entsprechenden Signifikanz. Eine 
Ausnahme bildet PPARG. Bei diesem Gen wurde nur eine grenzwertige Signifikanz 
festgestellt. Interessanterweise wurden vorwiegend SNPs als assoziiert identifiziert, die 
keine Evidenz aus Kandidatengenstudien mitbrachten. Ein Beispiel ist hierfür die 
Genvariante Val103Ile des MC4R Genes. Alle der bisherigen assoziierten Genvarianten 
zeigen relativ moderate Effektwerte und können somit die beobachtbaren Variationen 
nicht erklären. Ebenso kann die Summation der Effektwerte die Variationen nicht 
vollständig, bei den Plasmalipiden sind es z.B. 5-8%, erklären. Daraus lässt sich 
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schließen, dass es noch eine Vielzahl an assoziierten Genvarianten zu identifizieren gibt 
bzw. Umweltfaktoren einen großen Teil zur Variation beitragen. 
Zusammenfassend kann man sagen, dass Genvariationen die Entwicklung der MetSyn 
Komponenten sowie des MetSyn beeinflussen. Es ist allerdings noch unklar zu 
welchem Anteil dies geschieht. GWAS sind jedenfalls eine erfolgreiche Methode, um 
die Beteiligung der Gene bzw. die genetischen Determinanten des MetSyn und seiner 
Komponenten weiter zu untersuchen.  
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